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ABSTRACT

FACTORS REGULATING THE PRODUCTION OF
STX-2 IN ESCHERICHIA COLI 0157:H7
by
Kate P. Stefani
University of New Hampshire, May, 2010

The severity of Escherichia coli 0157:H7 disease is due in part to a major
virulence factor produced by the microbe, the shiga-like toxin 2 (Stx-2). Antibiotic
treatment to reduce pathogen numbers is controversial, as it is thought that antibiotics
may increase the levels of Stx-2 released from the pathogen. Currently, recommended
treatment for E. coli 0157:H7 is palliative The purpose of this study was to examine
three critical factors potentially important to disease outcomes, and to determine their
effect on expression of the stx2 gene and on release of Stx-2 from the pathogen. Those
factors selected for study were: i) various classes of antibiotics; ii) probiotic
microorganisms; and iii) carbon source variation together with cAMP.

Stx-2 was

assessed using MTT cytotoxicity assays and ELISA analysis, while the expression of stx2
was assessed using real time PCR. It was determined that antibiotics that affect microbial
DNA increased stx2 expression and Stx-2 production, and this was linked to an
upregulation in the SOS DNA repair response. A link was also observed between the
upregulation of stxl and those antibiotics that disrupt cell membrane integrity. However,
these antibiotics did not increase the overall levels of Stx-2 released from E. coli

xiv

0157:H7. The probiotic microorganisms Lactobacillus casei and L. plantarum were
found to decrease both stx2 expression and Stx-2 release when grown in co-culture with
E. coli 0157:H7 at greater or equal numbers to the pathogen. This reduction in Stx-2 was
at least in part attributable to organic acids produced by the probiotics, but other
unknown factors produced by the lactobacilli cannot be excluded.

Finally, it was

determined that growth of the pathogen in glucose-supplemented media yielded
significantly more stx2 expression and Stx-2 production than growth in glycerolsupplemented media. This observation was confirmed by a decrease in stx2 expression
and Stx-2 production when exogenous cAMP was added to culture media. The
examination of these three factors led to a clearer understanding of the intricacies
involved in the regulation of stx2, and has demonstrated how such an apparently diverse
group of external factors are interlinked through several complex mechanisms.

xv

CHAPTER 1

INTRODUCTION TO ESCHERICHIA COLI0151:K7
AND THE SHIGA-LIKE TOXIN 2

1.

Historical perspective
Escherichia coli 0157:H7 was first detected as a potential human pathogen in the

summer of 1982 after a number of people fell ill following the consumption of
contaminated hamburger (127, 170). During the course of this outbreak, a total of 47
people in Oregon and Michigan had symptoms of hemorrhagic colitis; severe abdominal
cramping and watery diarrhea that gave way to bloody diarrhea with little or no fever
(127, 170). Laboratory testing at the time excluded enterotoxigenic E. coli (ETEC) or
enteroinvasive E. coli (EIEC) as the causative pathogens (127, 170). Further testing
revealed a serotype (E. coli 0157:H7) not yet associated with human disease but present
in affected patients in 24 of 34 stools (103, 170).
The cause of this outbreak was presumed to be undercooked ground beef. All
patients reported to have eaten sandwiches at a fast food restaurant, with at least one of
three items in common: ground beef patty, rehydrated onion, or pickles (127).
Subsequent testing of ground beef samples held for examination revealed the presence of
E. coli 0157:H7, confirming this as the causative agent (127).
Two months later in November 1982, a second outbreak occurred in Ottawa,
Canada in a nursing home (103). Of 353 residents, 31 became sick, 8 with diarrhea and
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18 with hemorrhagic colitis (103). E. coli 0157:H7 was isolated from the stools of 17 of
31 patients with isolation of this serotype more common from those with hemorrhagic
colitis (103).

Ground hamburger meat was again suspected as it had been served

repeatedly during the time frame of the outbreak; however, no E. coli 0157:H7 was
isolated from the suspected meat (103).
The outbreak that brought E. coli 0157:H7 to public attention as a major
pathogen was the widely-publicized outbreak at the fast food restaurant chain Jack-inthe-Box in 1993 (8, 125). In the states of Washington, Idaho, California, and Nevada,
there were more than 500 laboratory-reported cases and four deaths (125). Eventually
these cases were directly linked to undercooked hamburger purchased at the Jack-in-theBox restaurants. In the wake of this outbreak, several recommendations were put forth
from state and federal government agencies regarding E. coli 0157:H7 and other strains
of enterohemorrhagic E. coli (EHEC) (26, 162). The following year E. coli 0157:H7
infection became a nationally notifiable disease (125). That same year, the Council of
State and Territorial Epidemiologists (CSTE) recommended that all bloody stools be
screened for EHEC using growth on a sorbitol-MacConkey agar medium (26), as most
EHEC strains are unable to ferment sorbitol, and are thus distinguished using this agar.
Likewise, in the wake of this major outbreak, the United States Food and Drug
Administration (FDA) released new guidelines for the cooking temperatures of ground
beef (162). By 2000, 48 of 50 states required state-level notification of this pathogen
(125).

2

2.

The Organism

2.1.

Taxonomy and Nomenclature
E. coli was first described by the German bacteriologist Theodore Escherich in

1885. E. coli 0157:H7 belongs to the kingdom Bacteria, the phylum Proteobacteria, the
class

Gammaproteobacteria,

the

order

Enterobacteriales,

and

the

family

Enterobacteriaceae. Both benign and human pathogenic serotypes are known to inhabit
the normal intestinal tract of warm-blooded mammals (56). A variety of E. coli serotypes
are found in the intestines of humans and are thought to contribute to intestinal health
through the production of vitamin K, the digestion of food, and by offering passive
immunity against other gastrointestinal pathogens (28, 45, 152). E. coli 0157:H7 is not
found in healthy individuals but is transiently cultured from the guts of cattle, and this
results in the incidence of this pathogen in ground beef (20, 58, 87).

2.2.

Phvsicochemical Properties
E. coli organisms grow optimally at gut temperature in the human body, 37°C.

Although this is the preferred temperature for E. coli, it is able to survive a much larger
range, from 19°C to 46°C (89).

The 0157:H7 serotype has a slightly narrower

temperature range of approximately 19°C to 41°C (124). It is interesting to note that this
serotype is unable to grow at 45°C, the temperature used to assess water samples for fecal
coliform contamination (124), and therefore would not be detected by traditional fecal
coliform assays. E. coli 0157:H7 can survive freezing when inoculated into ground beef
and remain viable when the meat is thawed at a later date. When stored initially at -80°C
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and held at -20°C, organisms remain viable for 9 months or more (96).
Thermal inactivation of E. coli 0157:H7 occurs optimally at 155°F (68°C) and all
organisms are killed within 15 sec at this temperature; indeed it shows no more tolerance
to cooking temperatures than do salmonellae (89).

The recommended internal

temperature for ground beef is 160°F (71.2°C), which will kill all E. coli 0157:H7 (89).
However, the 1997 Food and Drug Administration Food Code (96) requires a minimum
internal temperature of 155°F (68.5°C) with a 15 second holding time (96).
E. coli 0157:H7 has no growth factor requirements; metabolically it can utilize
glucose as a sole carbon source to produce any macromolecular components necessary
for growth of the cell (101). The organism is a facultative anaerobe; it is capable of
growing aerobically, but also can grow anaerobically by using NO3, NO2 or fumarate as
final electron acceptors (101). This ability allows E. coli to colonize the anaerobic lower
colon.
Although E. coli can survive at low pH, (as low as pH 2 for several hours),
growth of these organisms is limited to a pH range of 4 to 9 (145). It is believed that the
acid tolerance displayed by these organisms contributes to their low infectious dose
(thought to be 10-100 organisms total ingested) (9, 51). Three general mechanisms have
been proposed as to how E. coli can withstand such extreme pHs: i) a buffering due to the
E. coli cell's cytoplasm, ii) low proton permeability of the bacterial membranes, and iii)
the exclusion and excretion of protons from the bacterial cytoplasm by membrane-bound
proton pumps (9). These theories are in part supported by the limited growth and
survival of E. coli in low pH due to weak acids (133). In a study by Benjamin, et al.,
microbial growth was severely reduced in benzoic acid (9). Unlike a strong acid, which
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is dissociated outside of the cell, weak acids enter cells in an undissociated state and
dissociate within the microbe, releasing the proton and subsequently lowering
cytoplasmic pH (60, 131, 133). In the case of the three suggested mechanisms for how E.
coli tolerates low pH due to a strong acid, both ii) low proton permeability of the
membrane, and iii) the exclusion and excretion of protons, are null in the case of a weak
acid. The buffering capability of the cytoplasm (i) above) may not be sufficient on its
own to withstand an extreme pH by weak acids. Of interest is the observation that once
these acid resistance systems are turned on, they remain on for prolonged periods,
particularly when the organisms are stored at cold temperatures (4°C) (96). This acid
tolerance allows E. coli 0157:H7 organisms to grow in a variety of acidic foods, such as
mayonnaise, apple cider and salami (96), all of which have been associated with
outbreaks of disease due to this agent.
In contrast to its relative tolerance to acidic conditions, E. coli 0157:H7 shows no
outstanding tolerance to high sodium chloride concentrations. Unlike other food borne
pathogens such as Listeria monocytogenes and Staphylococcus aureus, this pathogen
cannot survive in more than 6.5% NaCl (96).

2.3.

Cultural and Morphological Characteristics
E. coli 0157:H7 displays similar colony morphology to other strains of E. coli.

Colonies readily appear after overnight growth at 37°C. On a standard medium such as
Luria-Bertani (LB) agar, growth appears as slightly translucent, small to medium sized,
off-white, convex, smooth colonies. On a slightly richer medium such as Mueller-Hinton
agar or trypticase-soy agar, the morphological characteristics are identical but colonies
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are usually somewhat larger.
The cellular morphology of E. coli 0157:H7 is identical to non-pathogenic strains
of E. coli. All are found as individual gram-negative cells in a classic coccobacilliary
shape and divide by binary fission at the polar ends. Table 1.1 summarizes the cellular
morphology of E. coli 0157:H7. The serotype 0157:H7 refers to the somatic (surface
antigen) serotype number 157 and the flagellar antigen serotype number 7 (11, 71, 122).
In the United States, the 0157:H7 serotype is the most prevalent and has attained the
greatest notoriety, however, numerous other serotypes of EHEC are present, and these are
often referred to as non-0157 isolates when citing incidence and outbreak details. These
serotypes include (but are not limited to): 026:H11, 091:H21, 022:H8, O103:H2,
04:NM, 05:NM, 0111:NM, and 0145:NM (where NM is non-motile) (96).
E. coli 0157:H7 produces lipopolysaccharide (LPS) as part of its surface
structure. LPS is highly antigenic to patients suffering from these infections, and often
illicit a strong inflammation response. LPS triggers platelet activation, one of the
hallmark features of the deadly complication, hemolytic uremic anemia (HUS) (149), as
discussed later.

2.4.

Biochemical Properties
The biochemical profile of E. coli 0157:H7 is similar to that of the commonly

used laboratory strain E. coli K-12. Results are identical on eosin methylene blue (EMB)
agar, MacConkey (MAC) agar, Hektoen enteric (HE) agar, triple sugar iron agar (TSI)
slants, citrate (CIT) slants, motility-indole-ornithine (MIO) agar tubes, urea (URE) broth,
as well as the oxidase (OX) test. The majority of E. coli 0157:H7 strains are unable
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Table 1.1. Morphological Characteristics of E. coli 0157:H7 Cells
Cell shape

Coccobacillus, short bacillus

Cell arrangement

Singular

Cell size

1.1 to 1.5 [im wide by 2.0 to 6.0 \im long

Gram reaction

Gram negative

Motility

Yes, multiple polar flagella

Attachment features

Fimbriae, intimin

Oxygen needs

Facultative anaerobe
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to ferment sorbitol, making sorbitol-MacConkey agar plates (sMAC) useful for the
differentiation between 0157:H7 and nonpathogenic serotypes (52). Table 1.2 provides a
summary of the biochemical properties of E. coli 0157:H7.

2.5.

Genetics of E. coli Q157:H7
E. coli 0157:H7 has a single, circular chromosome with a genome size of 5.49

Mb. This allows for 5361 protein coding genes, 104 tRNA genes and 22 rRNA genes.
The genome has a G+C content of 50.53% (64). There is also a 92 kb plasmid, p0157,
which codes for several virulence factors in the organism including espP (an extracellular
serine protease-coding gene), hlyA (a hemolysin-coding gene), katP (a periplasmic
catalase-coding gene), and toxB (a toxin gene, similar to one of Clostridium difficile)
(18). Due to the number of virulence genes located on it, it is thought that this plasmid is
crucial to the full pathogenicity of E. coli 0157:H7 (70). A particularly important
bacterial feature on this plasmid is the gene for the production of fimbriae.

These

structures allow adherence of E. coli 0157:H7 to host cells, and in the absence of this
plasmid, E. coli 0157:H7 has reduced virulence (70).

2.6.

Environmental Aspects
E. coli 0157:H7 is a disease of the human gastrointestinal tract; however, it is

rarely transmitted person-to-person.

Most individuals contracting the disease do so

through a non-human reservoir, usually food or beverages that have been contaminated
by cow manure or pasture runoff (50). The organism is near ubiquitous in cattle farms

Table 1.2. Biochemical Profile of E. coli 0157:H7 and E. coli K-12
Medium/Test

E. coli 0157:H7

E. coli K-12

EMB

Growth, Lac +

Growth, Lac +

MAC

Growth, Lac +

Growth, Lac +

sMAC

Growth, Sor -

Growth, Sor +

Growth, Lac/Suc/Sal +

Growth, Lac/Suc/Sal +

TSI

A/A, Gas+, H2S-

A/A, Gas+, H2S-

err

Cit-

Cit-

MIO

Mot +, Ind +, Orn +/-

Mot +, Ind +, Orn +/-

URE

Ure-

Ure-

ox

Ox-

Ox-

HE
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across the United States, with a positive carriage rate of 1-2% of animals on a farm or
feedlot on average (some seasonal variability occurs with carriage rates higher in warmer
weather) (50, 56, 126). Despite this high carriage rate, the organism is a transient
member of the normal flora of the cattle (56). Sampling populations of cattle reveals a
steady rate of carriage, although carriage by the individual animals varies with time. Put
another way, although a constant rate of 1-2% of animals carry the organism on a
particular farm, the individuals that make up that percentage varies with each sampling.
Therefore, the microbe is quite mobile between animals living in close contact and
sharing water and food troughs (56, 126). These organisms are not pathogenic to cattle,
but rather act like any other nonpathogenic strain of E. coli with colonization coming and
going with an average duration of two months (87). It should be noted that juvenile
animals are normally more prone to carriage of E. coli 0157:H7, possibly due to a lower
stability in their normal microbial gut flora (50).
Because of the close association of EHEC infections with cattle runoff and ground
beef, numerous models have been proposed for the control of this pathogen within cattle
populations. Eradication is likely an unachievable goal as this organism is carried within
environmental niches (such as contaminated food and water troughs) as well as in wild
animal populations (56, 87). In addition, E. coli 0157:H7 has been found in sheep, dogs,
horses and birds, and these may also serve as reservoirs for the pathogen (56, 87).
Pre-slaughter testing of cattle for EHEC has been suggested, but this is also likely
to prove unsuccessful. Indeed, current regulations state that a group of cattle must be
rejected if any animal tests positive for EHEC. As most slaughter groups are greater than
100 animals and with a 1-2% carriage rate, most groups would be rejected at slaughter
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with huge economic losses. New guidelines are required before this type of pre-slaughter
testing would become enforceable or even feasible (56).
In order to reduce both the percent of animals carrying E. coli 0157:H7 and to
reduce the number of E. coli 0157:H7 carried by a particular animal, several measures
have been put in place. One practice suggested was the withholding of food before
slaughter in order to reduce the amount of waste in the gut of the cattle, thereby lessening
the chance of contamination of due to gastrointestinal puncture during the slaughter
process. However, fasting decreases the stability of the normal flora within the animal,
which increases both the likelihood of colonization by transient E. coli 0157:H7, and
increases the amount of E. coli 0157:H7 organisms within already-colonized animals,
due to the reduction of normal flora organisms (126).

Another possibility is the

purposeful colonization of the cattle gut with competing organisms. This strategy has
been successfully applied in the broiler chicken industry to reduce contamination by
species of Salmonella (107). This method may be of interest especially in the case of
juvenile cattle in which it has been proposed to stabilize their intestinal flora with benign
microbes, so that EHEC colonization would prove difficult. This proposal is referred to
as competitive exclusion (20, 56). Competitive exclusion cultures can be made up of a
single species or of many types of bacteria and are designed to compete against
undesirable organisms. Three mechanisms are proposed by which these probiotics inhibit
the colonization of pathogens: i) competition for nutrients; ii) competition for binding
sites on the epithelium; and iii) production of various compounds that prove toxic to the
invading organisms (20, 28, 107, 150). Studies are on-going to determine the efficacy of
this approach.
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3.

Shiga-like toxin 2
Although there are numerous virulence factors associated with E. coli 0157:H7

that distinguish it from benign E. coli serotypes, the most notable and most deadly are the
shiga-like toxins, Stx-1 and Stx-2. Stx-1 and Stx-2 are so named for their similarity to
the closely related Shiga toxin (Stx) produced by Shigella dysenteriae serotype 1 (43).
The most devastating of infections are usually associated with Stx-2-producing strains of
EHEC, and it is these strains that are most often associated with the development of the
life-threatening condition hemolytic uremic syndrome (HUS) (75,113). This research
concentrates on the more deadly Stx-2.
Although Stx is produced by S. dysenteriae, and Stx-1 and Stx-2 are produced by
EHEC, Stx and Stx-1 are a relatively homologous group compared to Stx-2. In fact, the
A subunit of Stx and Stx-1 differ only by one amino acid residue, with position 45 in Stx
being serine while in Stx-1 it is threonine (5, 43). The A subunits of Stx-1 and Stx-2
have only 55% similarity (5). Also of note is that while Stx-1 is homogenous, Stx-2
exists as variants. Within the Stx-2 group are Stx-2c (63, 83), Stx-2d (115, 116, 119),
Stx-2d-activable (115, 116, 119), Stx-2e (54, 91), and Stx-2f (49, 139). These variants
are distinguishable by biological and immunological activity and each one binds unique
receptors (80). It should be noted, however, that all Stx-2 and its variants preferentially
bind the Gb3 receptor (Gall- 4Gall- 4glucosyl ceramide) (84, 163, 169).

3.1.

Structure of Stx-2
The structure of Stx, Stx-1 and Stx-2 all conform to the classic AB5 toxin

structure. The A subunit is responsible for the catalytic activity of the toxin, and thus the
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damage it wreaks on target cells (43, 84, 136, 169). The A subunit is further divided into
the Al and A2 fragments. The Al fragment, at 27.5 kDa, causes the enzymatic activity
of the toxin while the A2 fragment, at 4.5 kDa, connects the A subunit to the B subunit
pentamer.

The five identical B subunits are responsible for binding to target cells,

allowing entry of the toxin (43) (Figure 1.1.).
Several key differences have been cited between the structures of Stx/Stx-1 and
Stx-2. In Stx and Stx-1, the active site of the enzyme is blocked by the polypeptide A2
fragment and remains so until the A subunit is cleaved from the B subunit during entry
into a host cell (42). In Stx-2, the active site of the enzyme is active in the holotoxin.
The increased availability of the Stx-2 active site may be a factor contributing to the
greater pathogenic potential of Stx-2 and its documented links to the development of
HUS (43). In addition, the conformational arrangement of the Stx-2 B subunit pentamer
appears to be different from that of the Stx and Stx-1 B pentamers. These different
conformational perspectives could explain the different binding affinities of these
pentamers to the host cell Gb3 receptors (43). Likewise, the Al peptide of the A subunit
in Stx-2 appears to bind, and therefore block, one of the receptor sites in Stx-2, reducing
by one the number of available binding sites on the pentamer. This too could contribute
to the different affinities of Stx-2 for Gb 3 (43, 169).

3.2.

Mode of Action of Stx-2
The AB5 toxin structure is essential to the mode of action of the toxin. In essence,

toxins enter human intestinal cells by attachment of the B subunit to the Gb3 receptor, a
globotriaosyl ceramide (Gala(l-4)-Gaip(l-4)-Glcpi-ceramide) receptor (84, 114, 163).
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t
Al

Figure 1.1. Schematic Representation of Stx-2. Stx-2 is an AB5 toxin. The A subunit
is comprised of two separate fragments, Al and A2. The Al fragment has the enzymatic
activity of the toxin and the A2 fragment serves as a connector to the five identical B
subunits. The B subunit pentamer binds the toxin to appropriate receptors on host cells.
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The holotoxin is endocytosed and retrograde transported to the Golgi network and
subsequently to the endoplasmic reticulum (95). At this post-endocytosis point, the A
subunit is cleaved by furin, a membrane-bound protease similar to the enzyme trypsin,
and this yields the Al and A2 fragments. The Al fragment then targets the ribosome
(95). Al has RNA N-glycosidase activity that cleaves a specific N-glycosidic bond in the
28S rRNA of the 60S ribosomal subunit, removing an adenine base. This base is an
integral component of elongation factor binding to the ribosomal subunit, and therefore
prevents the affected cell from carrying out protein synthesis (39, 114, 136, 144). Toxins
may also enter the blood stream, travel to the kidneys, brain, and other organs, and cause
extensive cell and tissue death leading to major organ failure and system collapse (71).

3.3.

Genetics of stx2
The stx2 gene is located on a lambda-like bacteriophage (BP-933W) inserted as a

prophage into the chromosome of E. coli 0157:H7. When the organism is metabolically
stable, the prophage remains in a lysogenic state, leading to low or baseline level
expression of stx2. However, when the E. coli 0157:H7 host bacterium is subjected to
stress, the prophage converts to a lytic state and is excised from the chromosome (166).
During excision, the stx2 gene is co-expressed with phage genes due to their proximity on
the phage chromosome and this leads to an increase in toxin production (57, 78, 104,
164). Upregulation of stx2 gene expression is believed to be the end result in a cascade
pathway that begins with the activation of the RecA protein by damaged DNA (57, 164).
The genetic system of the E. coli BP-933W bacteriophage is complex, selfrepressing, and self-regulating (Figure 1.2, 1.3). When the regulating proteins ell and
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cIII are expressed at low levels they activate the repressor cl. CI in turn binds and
represses the promoters, ProL and ProR, to stop transcription of a majority of the phage
genome, including ell and cIII and the toxin gene, stxl (44, 86, 164). Thus, the system is
self-repressing and self-regulating, i.e. it blocks transcription of the phage genome,
maintaining the phage in a lysogenic state, unless a stress trigger interrupts the cycle.
This interruption can occur following DNA damage, which leads to initiation of the SOS
DNA repair system that in turn activates RecA. When the SOS response is initiated,
activated RecA degrades the regulating protein, ell and hence the expression of cl is also
arrested. Without expression of the cl repressor, the late phage genes are expressed, and
these include stxl (44, 78, 104, 120, 164).

Conversion to the lytic cycle is a

bacteriophage survival mechanism effected when host DNA is compromised. The stxl
gene is located between the late phage promoter and phage-excision genes and is cotranscribed when host cell damage is sensed.

Therefore, under DNA damaging

conditions, induction of phage genes and stxl occur simultaneously (44, 74, 86, 164).

4.

Clinical and Epidemiological Findings

4.1.

Clinical Presentation
E. coli 0157:H7 causes a variety of disease states, depending on the age and

general health states of the infected individual, as well as the dose of organism ingested
(123, 101, 127, 114). In its mildest form, the disease presents with symptoms of diarrhea
and stomach cramping lasting up to five days.

More severe cases often show

hemorrhagic colitis (HC) or bloody diarrhea (Table 1.3.). In the most severe cases
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VD

Mild

10%

Diarrhea (non-bloody)
Abdominal cramps
None

Se\erit>

Approximate percentage
of cases
Symptoms

Complications

Hemorrhagic colitis
Abdominal cramps
HUS, TTP

None

5-15%

Se\ere

Hemorrhagic colitis
Abdominal cramps

70-85%

Modest

Table 1.3. Different Clinical Manifestations of EHEC Disease

(approximately 5% of patients) these gastrointestinal symptoms are followed by a
complex presentation of symptoms culminating in hemolytic uremic syndrome (HUS)
(114); an often fatal complication especially in children, the elderly, and the
immunosuppressed. HUS is characterized by hemolytic anemia, thrombocytopenia, and
renal failure. Hemolytic anemia results from the fragmentation of red blood cells as they
pass through areas of thrombi in the small blood vessels.

These sheared cells are

characteristic of HUS during microscopic examination of patients suspected of having
this condition. Low circulating platelet counts are a predictor, as platelets adhere to the
damaged vascular endothelium and are removed from circulation.

It has also been

suggested, but not proven, that Stx-2 may interact directly with platelets, reducing their
count (123).

Renal damage occurs as these sheared red blood cells and platelets

aggregate in the small blood vessels of the kidneys (123).
In some cases there may be neurological involvement and a fluctuating fever.
Often these neurological symptoms are associated with a distinct but very similar
condition, thrombotic thrombocytopenia purpura (TTP) (101, 123, 130). Both TTP and
HUS are microangiopathic disorders that are Characterized by abnormalities in the small
blood vessels of the body. The key difference between these conditions is the location of
the microvascular thromboses.

In TTP they can be found in the brain leading to

neurological symptoms, and also in the skin, intestines, skeletal muscle, pancreas, spleen,
adrenal glands, and heart. In HUS, these microthrombi are confined to the kidneys (123)
(Table 1.4).
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Table 1.4. Comparison of HUS and TTP

Age affected
Microscopic examination of
blood
Peripheral smear
Organs affected

Treatment
Prognosis

HUS

TTP

Children
Anemia

Adults
Anemia and
thrombocytopenia
Microangiopathic
hemolytic anemia
Predominantly CNS, but
also intestines, pancreas,
skin, heart, spleen and
others
Palliative, plasmapheresis,
steroids
Poor

Microangiopathic
hemolytic anemia
Kidneys

Palliative, dialysis,
plasmapheresis
Good
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It is important to note that, as mentioned previously, HUS occurs considerably more
often in children than in adults, and in fact is the most common cause of kidney failure in
children in the United States (105). Indeed, in the United States, the average annual
incidence is 2.65 cases per 100,000 individuals under 5 years old. In individuals 5-18
years old the incidence is notably lower, 0.97 cases per 100,000 (123, 125).

2.1.

Pathology
Symptoms of an E. coli 0157:H7 infection usually occur within 3-8 days of

ingestion of the bacterium. The symptomatic phase of disease can be divided into two
phases: 1) before blood is present in the stool, and 2) after blood is present in the stool
(101, 123, 130).

However, in approximately 10% of reported cases there is no

progression beyond phase 1 (123).
The first symptoms, preceding even the non-bloody diarrhea, include severe
abdominal cramping and general irritability. These symptoms are often enough to induce
a missed day of school or work, but do not often warrant a visit to the physician. After
the onset of non-bloody diarrhea, an over-the-counter anti-diarrheal medication is often
administered. Such treatments often include an antiperistalitic agent (101, 123, 130). In
the case of EHEC infections, these medications are generally contra-indicated as they can
slow the clearing of the organism from the body, allowing more time for colonization and
toxin production (123, 130). Although most physicians are aware that antiperistalitic
medications are detrimental in cases of EHEC infections, before the presence of blood in
the stool there may be little or no reason to consider that an EHEC infection exists; nonbloody diarrhea is a common enough event. Bloody diarrhea often occurs within 1-3
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days of the non-bloody diarrhea, and in most cases prompts a visit to a physician (123).
At this point an EHEC infection is usually suspected and can be confirmed through
laboratory tests (52). Lastly, in 5-15% of EHEC cases, infections progress to HUS. Often
the first clinical symptoms of HUS are a diminished platelet count, followed by
hemolytic anemia (123).
Hemolytic anemia is the cardinal feature of HUS; the patient may appear more
pale than normal, and have abnormal swelling in the extremities. In blood smears,
fragmented red blood cells are common. Thrombocytopenia occurs due to the increased
clotting and destruction of platelets (123). Immunoglobulin G (IgG) concentrations in
the blood serum decrease, while IgA and IgM elevate. Often IgM deposits are noted in
the injured glomeruli of the kidneys (80, 123). In one-third of patients, blood pressure is
elevated due to a combination of fluid replacement therapy and kidney dysfunction. This
requires close monitoring to avoid harm to the patient. Urinalysis is abnormal with
hematuria, proteinuria, and red blood cell cast-off cells (101).
Commonly, hepatomegaly is a finding in cases of HUS due to fluid overload and
hypoalbuminemia. Despite these symptoms, liver failure and long-term hepatic sequelae
have not been reported.

In 10-20% of HUS cases, the pancreas is affected, though

clinical pancreatitis is unusual. In 4-15% of patients, insulin-dependent diabetes mellitus
occurs due to islet cell necrosis (130).

2.2.

Pathogenesis and Virulence Factors
The pathogenesis of EHEC infections begins shortly after ingestion of the

bacterium. It is believed that the infectious dose of E. coli 0157:H7 may be as low as 10
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to 100 organisms (81,114). These organisms are able to survive the acidity of the human
stomach and proceed to colonize the lower gastrointestinal tract (82, 93, 133). E. coli
0157:H7 is not considered invasive. That is, it does not burrow into the epithelial cell
layer, as organisms like Shigella dysenteriae do. It does associate closely with the
intestinal epithelial layer, resulting in the formation of attaching and effacing lesions (69,
70,108,117,118).
Attaching and effacing lesions are induced in part by the production of the 94 kDa
to 97 kDa outer membrane protein intimin (69). Attaching and effacing lesions cause
polymerization of actin filaments in the epithelial cells of the intestines, forming a
characteristic pedestal that binds the E. coli 0157:H7 cell. The microvilli are effaced
from the intestinal lining (69, 117, 118). The intimin protein is encoded by a gene, eae
(E. coli attaching and effacing), which is located chromosomally on the 35 kb locus of
enterocyte effacement (LEE) pathogenicity island (37, 38). Upstream of the eae gene is
the tir gene, which encodes the translocated intimin receptor, or Tir protein.
Interestingly, Tir becomes the receptor on the eukaryotic cell for intimin, but it is
produced by the E. coli 0157:H7 cell. Tir is then shunted into the eukaryotic host cell
through a type III secretion system. Once inside the host cell, Tir is phosphorylated and
interacts with the host cytoskeleton and intimin (69). Intimin-independent adherence to
host epithelial cells has been suggested through type 1 fimbriae, however, it should be
noted that only a minority of E. coli 0157:H7 strains produce fimbriae in vitro, and that
the role of fimbriae in E. coli 0157:H7 colonization is not established (159). For E. coli
0157:H7, investigation of microbial adherence is problematic, as the toxins produced are
often lethal to the host cells before adherence can be observed.
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The LEE pathogenicity island (Figure 1.4.) is thought to have been horizontally
transferred from another microorganism. The most striking proof of this is that the G+C
content of the LEE pathogenicity island is 38.3%, compared to the 50.8% G+C content of
the rest of the E. coli 0157:H7 chromosome (37). Besides eae and tir, other virulence
genes are located on the LEE pathogenicity island. Upstream of eae and tir are numerous
genes, including esc and sep, that encode the type III secretion system necessary to
translocate Tir into the host epithelial cell. Downstream of eae are a number of esp
genes, which encode proteins responsible for epithelial cell signaling in the formation of
the attaching and effacing lesion. Overall, the LEE pathogenicity island encodes all the
necessary proteins for the production of an attaching and effacing lesion (37).
E. coli 0157:H7 has a unique iron scavenging system efficient enough to utilize
heme or hemoglobin as an iron source. This 69 kDa outer membrane protein is encoded
by the chuA gene, which is turned on in iron-limiting conditions (111). The lysis of red
blood cells (a known symptom of HUS) could aid in the pathogenesis of E. coli 0157:H7
through the release of hemoglobin thus increasing the amount of iron available to the
pathogen.

Likewise, E. coli 0157:H7 produces several hemolysins; the most

characterized being the extracellular alpha-hemolysin (70, 140). Distinct from this is an
enterohemolysin, named Ehyll, which is carried on the plasmid p0157. Although this
phenotype is often lost quickly in vitro, anti-Ehyll IgG has been detected in patients
recovering from HUS, suggesting its presence during EHEC infections (70).

Also

located on the p0157 plasmid is the gene katp, which encodes a catalase-peroxidase
enzyme, KatP. This enzyme contains an amino-terminal signal peptide that suggests it is
transported through the cytoplasmic membrane, and is mostly found in the periplasm.
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esp

The locus of ©ntorocyte effacement (LEE) of E2348/69

KatP is deemed a bifunctional enzyme, possessing both catalase and peroxidase
activities, making it a potent virulence factor when expressed inside the human host (70).
The genes and the products they encode for the principal virulence factors of E. coli
0157:H7 are outlined in Table 1.5.
Once colonization of the pathogen is established (through the aid of intimin, Tir,
attaching and effacing lesions and the other virulence factors), Stx-2, arguably the most
important of the diverse virulence factors, is released from the E. coli 0157:H7. Stx-2
molecules translocate across the epithelial layer using an energy-dependent process,
though the mechanisms of this movement are not elucidated (62).

What is clear,

however, is that the toxin crosses the epithelial cell barrier in a transcellular pathway, as
tight junctions between cells remain intact. Stx-2 appears to bind less tightly to epithelial
cells than does Stx-1 and may allow a greater proportion of toxin to enter the blood
stream from the intestines (62). This could offer, at least in part, a rationale for the higher
virulence and greater severity of disease reported for Stx-2 producing strains. Data
suggest that Stx-2 could stimulate the secretion of interleukin-8 (IL-8) by intestinal
epithelial cells, resulting in neutrophil migration to that tissue. Neutrophils are possible
carriers of Stx-2 to the various organs of the patient, including the kidneys (165).
Once translocated across the epithelium, Stx-2 acts on endothelial cells and
platelets in the microvascular network, leading to thromboses as seen in pathology
studies. Endothelial cells are highly sensitive to Stx, and those of the microvascular
endothelial cells are especially so (108). Such findings confirm the pathological data
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Table 1.5. Virulence Factors of E. coli 0157:H7
Gene
stx2A
stx2B
eae
tir
esp
esc
sep
chuA
ehyll
katP
etpCetpO

Location
Chromosome,
933-W phage
Chromosome,
933-W phage
Chromosome,
LEE island
Chromosome,
LEE island
Chromosome,
LEE island
Chromosome,
LEE island
Chromosome,
LEE island
Chromosome
p0157plasmid
p0157plasmid
pO!57 plasmid

Gene product/function
A subunit of Stx-2
B subunits of Stx-2
Intimin, A/E formation
Tir, A/E formation
Esp proteins, signal transduction for A/E
formation
Type III secretion for the Esp proteins
Type III secretion for the Esp proteins
Heme utilization, iron transport system
hemolysin
Catalase-peroxidase
Type II secretion system
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that show that the colonic, neural, pancreatic, pneumonic microvasculature are much
involved in HUS and TTP (123).

2.3.

Epidemiology
E. coli 0157:H7 causes 73,000 reported cases of disease in the US each year.

Kidney damage and HUS occurs in 5-15% of cases. This condition usually occurs in
children under 5 years old, and is the leading cause of acute kidney failure in children in
the US (105). Annually approximately 60 of these illnesses result in death (125).
E. coli 0157:H7 is usually foodborne or waterborne and a number of foods and
beverages have served as the source of outbreaks. These include ground beef, lettuce,
alfalfa sprouts, apple juice, and apple cider (50) (Figure 1.5). Many waterborne cases
have also been reported from both drinking and recreational waters. Less commonly are
outbreaks and sporadic cases caused by non-food and water sources, such as petting zoos
and contact with farm animals. Person-to-person spread is rare (50, 125).
A distinct seasonality of E. coli 0157:H7 is seen with warmer months having
higher incidence, due possibly due to increased shedding by cattle coupled with increased
consumption of ground beef and less careful food handling during barbeque season (40)
(Figure 1.6).
A number of risk factors may increase the likelihood and severity of the disease.
Children under 5 years old are at the most risk and may develop HUS. It is unknown
why children are so exquisitely susceptible to develop this condition although the
relatively small size of children's blood vessels may facilitate easier damage by Stx-2
(125).
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Figure 1.5. Transmission Routes for E. coli 0157:H7.
invariably cattle (50).

Note that the origin is
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observed showing a higher summer incidence (40).
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To offer confirmatory evidence, even the smaller blood vessels of adults are more
susceptible to damage by the toxin than are the large blood vessels. Damage to the
kidneys is due largely to microthrombi leading to blockages in the microvasculature of
these organs (125). It is possible that a smaller dose of toxin would cause greater damage
overall to children than to adults. The less mature immune system of children further
complicates this scenario.
Other factors that increase the risk of E. coli 0157:H7 infection include unsafe
handling of raw meats, as well as consumption of raw and undercooked meats,
unpasteurized beverages (such as apple cider and milk), and contaminated produce.
Gender does not appear to be a factor in the likelihood of contracting disease (40).
As would be expected, the reported incidence of outbreaks increased after the first
cases in 1982. However, such increase was likely due to a heightened awareness of the
pathogen, and the mandatory reporting of cases of EHEC infections (Figure 1.7) (125).
The trend in E. coli 0157:H7 infections has declined between 1996 and 2007 (Figure 1.8)
(40). In 2003 and 2004, the lowest rates of infection were reported but these were
followed by two years of higher incidence followed by a decrease again in 2007 (40).
Hand-in-hand with the incidence of E. coli 0157:H7 disease is the incidence of HUS.
Fortunately, the number of outbreak-associated HUS cases has declined since 1982, with
a few spikes in frequency. The relative number of HUS cases also dropped in 2003 and
2004, coinciding with the lower incidence of E. coli 0157:H7 cases (Figure 1.9) (40).
Likewise, as can be seen in Figure 1.10, the number of HUS-associated deaths has
declined since the 1982 outbreak (125). This is most likely due to greater awareness of
the organism.
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Figure 1.7. Reported Cases of E. coli 0157:H7 from 1982 to 2002. Note the dip in
incidence in 1997 when PulseNet for E. coli 0157:H7 was implemented (125).
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Figure 1.8. Relative Rates of K coli 0157:H7 Infection. The overall trend in disease is
declining. The years of 2003-2004 had the lowest rates of infection, but were followed
by two years of higher incidence before decreasing again in 2007 (40).
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Figure 1.9. Relative Rates of 2?. coli 0157:H7-associated HUS. The relative number of
HUS cases dropped dramatically in 2003 and 2004, coinciding with the lower incidence
of E. coli 0157:H7 cases (40).
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Figure 1.10. Number of Cases of HUS in Comparison to Case-fatality Rate. Overall,
the number of cases of HUS has decreased, along with the proportion of fatal cases. This
could be due to increased awareness of E. coli 0157.H7 infections and their association
with HUS (125).
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Disease prevention is the same as for any gastrointestinal illness. Ground beef
should be cooked to a minimum of 160°F to kill all E. coli 0157:H7 (124).. It is also
important to keep raw meats separate from ready-to-eat foods, or foods that will not be
cooked. For example, knives and cutting boards should always be thoroughly washed if
they have been in contact with raw meat before re-using for vegetables or other foods.
Likewise, any fruits and vegetables should be washed thoroughly, particularly if they will
not be cooked before consumption.

Only pasteurized milk and juices should be

consumed, to prevent the risk of ingesting E. coli 0157:H7 from these beverages. When
swimming, care should be taken to avoid swallowing lake or pool water. People with
diarrhea should not be allowed to partake in recreational water activities until approved
by a physician. As with the prevention of any infectious disease, careful and thorough
hand washing with soap and warm water can greatly reduce the risk of acquiring or
passing on an infectious agent (125).

2.1.

Immune Response
In patients with HUS, increased concentrations of IL-6, IL-8 and TNF-oc have

been reported (80). These cytokines are produced by monocytes, which may be induced
to release these inflammatory mediators by Stx-2. Likewise, a significant correlation
exists between the neutrophil count in HUS patients and patients' outcomes. Children
with poor outcomes (severe disease) had higher neutrophil counts on admission to the
hospital. Similarly, patients who died of EHEC-associated HUS had significantly larger
numbers of neutrophils in the renal glomeruli than in controls (80). These data add to the
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suggestion that neutrophils are involved in Stx-2 carriage around the body during E. coli
0157:H7 infections.

2.4.

Treatment and Palliative Measures
Treatment of E. coli 0157:H7 infections poses a true dilemma for most

physicians. Most often, the patient is a child whose parents insist on treatment, yet
traditional treatments (such as anti-diarrheal agents and antibiotics) are contra-indicated
(97, 132, 171).
In the history of E. coli 0157:H7 infections, the use of antibiotics has been both
variable and controversial. In the first report on E. coli 0157:H7 disease, two outbreaks
were outlined. A total of 47 cases were identified and 23 patients had available treatment
histories. Of those 23 patients, 11 were treated with antibiotics (8 with tetracycline and 3
with erythromycin). None of the 47 cases (including the 11 treated with antibiotics)
developed any complications (such as HUS) (127). This information indicates that
antibiotics are not detrimental to the outcome of E. coli 0157:H7 infections.

In a

subsequent outbreak in a nursing home, 22% of the 55 affected patients developed HUS,
and the mortality rate was 31%. Antibiotic therapy provided after onset was associated
with increased fatalities (103). In this outbreak, the majority of patients were elderly,
which may have contributed to the higher rate of complications and death. Nonetheless,
this outbreak caused physicians and scientists to rethink the use of antibiotics for treating
infections with this organism. A number of retrospective studies have been conducted on
the efficacy of antibiotics in treatment protocols and this topic is a key component of this
thesis. These details are discussed further in Chapter II. Currently, antibiotic treatment is
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divisive (132).

Although some physicians may continue to treat E. coli 0157:H7

infections with antibiotics, a majority agrees that antibiotics are more harmful than
helpful for combating this pathogen. Likewise, the use of antimotility agents (to reduce
diarrhea symptoms) has been associated with a higher risk of developing HUS, and
particularly HUS with central nervous system manifestations (97, 171).
Treatment is mainly palliative. Careful monitoring and rehydration therapy is
often used to replace fluids lost to vomiting (in some cases) and severe diarrhea in nonHUS E. coli 0157:H7 cases. In cases of HUS, the amount of fluids must be monitored
carefully as the kidneys may be under some considerable stress, and extremely high
blood pressure can result. Dialysis is often implemented to support kidney function and
in severe cases plasmapheresis may be required (123). In essence, the objective is to
remove circulating Stx from the blood in the hopes of reducing the damage to the
microvascular structure of affected organs (123).
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CHAPTER 2

THE EFFECTS OF SUB-INHIBITORY CONCENTRATIONS
OF SELECTED ANTIBIOTICS ON THE PRODUCTION OF
STX-2 BY ESCHERICHIA COLI 0157:H7

1.

Abstract
Shiga toxin 2 (Stx-2) is a major virulence factor contributing to the pathogenesis

of HUS and to overall E. coli 0157:H7 disease. The stx2 gene is located within the
genome of a lambda-like prophage, 933-W, and thus the genetic and physiological
mechanisms involved in the production of Stx-2 are complex and closely involve
induction or repression of the prophage. It was hypothesized that growth of the E. coli
0157:H7 in DNA-damaging antibiotics would increase stx2 expression and Stx-2 release
by initiating the bacterial SOS DNA repair response. Likewise, it was hypothesized that
growth of the pathogen in antibiotics that do not affect bacterial DNA (^-lactams, protein
synthesis inhibitors, cell membrane disruptors, and transcription inhibitors) would not
initiate the SOS DNA repair response, and therefore would not increase Stx-2 production.
E. coli 0157:H7 was grown in 90% MIC-level antibiotics, and at 1 and 6 h postinduction, the stx2 gene was assessed using quantitative Real-Time PCR. At 24 h postinduction, the production of Stx-2 toxin was measured using a capture ELISA, as well as
by MTT cytotoxicity assay. It was determined that stx2 expression and Stx-2 production
increased following microbial exposure to the DNA-damaging antibiotics ciprofloxacin,
norfloxacin, and trimethoprim, as well as with the positive control, mitomycin C. These
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results were concurrent with an upregulation in the DNA damage inducible gene, dinD.
No significant change was detected when the organism was grown in cefotaxime or
chloramphenicol.

Rifampin significantly decreased Stx-2 production and stx2

expression. Gentamicin and polymyxin B increased stx2 expression but did not increase
Stx-2 release, and this may be associated with the cell membrane-altering properties of
both these antibiotics. These studies suggest that stx2 expression and subsequent release
of Stx-2 are linked to the SOS DNA repair system, and that antibiotics that damage
bacterial DNA should be avoided in clinical use for E. coli 0157:H7 infections.
Rifampin may serve as a viable alternative for treating these infections given the decrease
noted in the stx2 expression and Stx-2 release; however, the rapid development of
resistance to this antibiotic may relegate it to a secondary role in combined therapy.

2.

Introduction
Escherichia coli 0157:H7 is the causative agent of "hamburger disease", a severe

type of food poisoning with symptoms ranging from profuse, watery diarrhea to the
bloody diarrhea of hemorrhagic colitis (HC) (8, 103, 125, 127, 170). In 5-15% of cases,
this disease escalates to HUS (75, 113), and unfortunately there is no curative treatment
for these infections. In the past, antibiotics were prescribed to combat the bacterium but
research has contra-indicated this approach (10, 97, 99, 109, 132, 156, 157, 171). Indeed,
one study showed a 17x higher rate of HUS development in children treated with
antibiotics compared to those not treated with antibiotics (171). Despite a wide range of
studies on the pathogenesis of E. coli 0157:H7, specific treatments aimed at the source of
the disease have not been forthcoming. Rather, most treatments are palliative, that is,
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they are associated with treating symptoms rather than eradicating the etiological agent
causing the disease. As such, research on the efficacy of antibiotic treatment of E. coli
0157:H7 infections is of value.
The principal virulence factors produced by E. coli 0157:H7 that initiate this
disease are the Shiga-like toxins (Stx), including Stx-2 (12, 14). The stx2 gene is located
on a lambda-like bacteriophage, BP-933-W, inserted as a prophage into the chromosome
of E. coli 0157:H7. When the microorganism is metabolically stable, the prophage
remains in a lysogenic state. However, if the E. coli host is subjected to stress, the
prophage converts to a lytic state and is excised from the chromosome (104, 164).
During excision, the stx2 gene is co-expressed with phage genes, leading to an increase in
toxin production. Upregulation of stx2 gene expression is believed to be the end result in
a cascade pathway that begins with the activation of the RecA protein by damaged DNA
(74). When the regulating proteins ell and cIII are expressed at low levels they activate
the repressor cl. cl in turn binds and represses the promoters, ProL and ProR, to stop
transcription of the majority of the phage genome, including the toxin gene, stx2. In this
manner, the system is self-repressing and self-regulating; it blocks transcription of the
phage genome unless something interrupts the cycle. This interruption occurs when
RecA becomes activated by DNA damage. RecA is a protein normally involved in
recombination events, but when activated it becomes a cellular protease. RecA causes ell
to be degraded and hence the expression of cl is arrested. Without expression of the cl
repressor, the late phage genes are expressed, including stx2 (78, 120, 164).

This

conversion to the lytic cycle is a bacteriophage survival mechanism effected when host
(E. coli 0157:H7) DNA is compromised. The stx2 gene is located between the late phage
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promoter and phage-excision genes and is co-transcribed when host cell damage is
sensed. Therefore, under DNA damaging conditions induction of phage genes and stx2
occurs simultaneously (74, 86, 166).
It was previously unknown if increased Stx-2 levels were due to an increase in
stx2 expression, or if it were simply lysis of bacterial cells which released pre-formed,
stored toxin.

Kirnmit et al. provided convincing evidence that genuine toxin gene

expression occurred in response to environmental stress (74). Specifically, Kimmit's
research showed that DNA-damaging antibiotics such as the fluoroquinolones and folate
synthesis inhibitors are the most potent inducers of the stx2 promoter (74). In a genomewide assay, Herold et al. demonstrated upregulation of a number of genes after treatment
with sub-inhibitory concentrations of the DNA-damaging antibiotic norfloxacin (57). Of
significance, their study yielded a 150-fold increase in stx2 expression in the presence of
high levels of norfloxacin.

They surmised that with very low concentrations of the

antibiotic, E. coli was using an alternate RecA-independent DNA repair pathway.
However, when high, near-inhibitory concentrations were employed, the "last-ditch" SOS
response of the bacterium was activated which increased stx2 induction (57).
In 2007, Ochoa et. al showed that the transcription-inhibitor rifaximin did not
induce Stx-2 or 933-W phage release, as opposed to the DNA-damaging antibiotic
ciprofloxacin, which increased Stx-2 production in 96% of strains evaluated (109). This
confirmed previous hypotheses that DNA-damaging antibiotics lead to an increased
production of Stx-2, and thus should be avoided in clinical situations involving E. coli
0157:H7. However, whether all antibiotics or just those that affect bacterial DNA should
be avoided as clinical treatment for these infections has yet to be elucidated.
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In the current study, the production of Stx-2 and the activity of stx2 were
measured when the organism E. coli 0157:H7 was grown in sub-inhibitory
concentrations of various antibiotics.

These were selected from a wide variety of

antibiotic classes, and included a broad range of bacterial targets. Those antibiotics
studied were: i) cefotaxime, a cell wall inhibitor; ii) ciprofloxacin, a DNA gyrase
inhibitor; iii) chloramphenicol, a protein synthesis inhibitor; iv) gentamicin, a protein
synthesis inhibitor; v) polymyxin B, a cell membrane inhibitor; vi) rifampicin, a
transcription inhibitor; vii) norfloxacin, a DNA gyrase inhibitor; and viii) trimethoprim, a
folate metabolism inhibitor. Mitomycin C was used as a positive control, as it has been
shown to be a potent mutagen that upregulates Stx-2 production (138). These antibiotics
were selected to comprise both DNA-affecting and non-DNA affecting drugs. Likewise,
polymyxin B was included because of its cell-membrane affecting abilities; it has been
suggested that Stx-2 is increased by some antibiotics simply due to bacteriolysis.
Polymyxin B is known to cause bacteriolysis (137) and in that respect serves as a
comparison control for other antibiotics.
Stx-2 production was measured by both cytotoxicity assays and by enzyme-linked
immunosorbent assay (ELISA).

The expression of the stx2 gene was measured by

quantitative Real Time PCR (q-PCR). In q-PCR studies, two additional genes were
investigated, serC (serine synthase) and dinD (DNA-damage inducible). The serC gene
was included because it is considered a "housekeeping gene"; it is constitutively
transcribed despite growth conditions (57). All results were expressed as a function of
serC activity to allow for differences in experimental techniques (efficacy of RNA
extraction, cDNA synthesis, etc.). The dinD gene is expressed when DNA damage is
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sensed within the E. coli 0157:H7 cell. If stx2 is upregulated because of damage to DNA
then the dinD gene should also be upregulated.

3.

Hypothesis
It was hypothesized that an upregulation in stx2 expression and an increase in Stx-

2 production would occur when the E. coli 0157:H7 was grown in DNA-damaging
antibiotics. Conversely, growth of the pathogen in antibiotics that target other parts of
the bacterial cell (excluding the DNA) were hypothesized to have no effect on stx2
expression or Stx-2 production.

4.

Materials and Methods
Media and reagent preparations are provided in detail in Appendix A.

4.1.

Bacterial Cultivation
The E. coli 0157:H7 strains 90-2380 and 43888 stock cultures were acquired and

maintained as described in Appendix B. Overnight and experimental cultures used in
antibiotic experiments were grown on Mueller-Hinton (MH) agar plates, or in MuellerHinton broths (MHB). All cultures were grown statically at 37°C.

4.2.

Vero Cell Growth and Maintenance
African green monkey kidney (vero) cells were maintained as described in

Appendix B. In preparation for cytotoxicity assays, vero cells were passaged into a 96well microtiter plate (Corning Life Science, Lowell, MA) as follows: Log-phase (60-
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70% confluent) vero cells in a T25 flask were rinsed twice with Hank's balanced salt
solution-modified (HBSS-mod). Following thorough rinsing, trypsin-EDTA solution was
added to the flask and allowed to incubate at room temperature for approximately three
min.

The cells were observed through an Olympus CK2 inverted phase-contrast

microscope (Olympus, Center Valley, PA) for removal from the bottom of the flask.
This was noted by the rounding up of cells as they released from the flask surface and
became free-floating in the liquid. The action of the trypsin was ceased by the addition of
five times the volume of Dulbecco's modified Eagle's minimal essential media (DMEM)
with three percent bovine calf serum (BCS). This suspension of free-floating vero cells
was centrifuged (IEC Centra, Waltham, MA) for five min at room temperature at 1000
rpm to pellet the cells. The supernatant fluid was carefully removed and discarded, and
the resulting pellet was resuspended in DMEM with 3% (v/v) BCS. A cell count was
performed in a hemocytometer using a dilution in the viability stain, trypan blue. Vero
cells were then seeded into the 96-well plates at a concentration of 10,000 cells/well.

4.3.

Minimum Inhibitory Concentration (MIC) Assays for Antibiotics
A minimum inhibitory concentration (MIC) assay was performed for each

antibiotic under investigation to determine the lowest concentration that could still inhibit
the growth of E. coli 0157:H7 strain 90-2380. A microliter plate method was utilized
(see Table 2.1), in which each row of the 96-well plate contained a 1:2 dilution of a
specific antibiotic; the last two columns did not contain antibiotic. Column 11 was used
as a no-antibiotic control and column 12 was a media-only control. The eight antibiotics
were prepared as listed in Appendix A. A standardized suspension of E. coli 0157:H7
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Table 2.1. MIC Plate Set Up.
Columns 1-10
A
B
C
D
E
F
G
H

Cefotaxime,
1:2 dilution, 10 mg/mL to 19.5 |ig/mL
Ciprofloxacin,
1:2 dilution, 1 |j.g/mLto 1.95 ng/mL
Chloramphenicol,
1:2 dilution, 100 ng/mL to 195 ng/mL
Gentamicin,
1:2 dilution, 100 jig/mL to 195 ng/mL
Polymyxin B
1:2 dilution, 10u,g/mL to 19.5 ng/mL
Rifampin,
1:2 dilution, 100 [ig/mL to 195 ng/mL
Norfloxacin,
1:2 dilution, 1 (ig/mLto 1.95 rig/mL
Trimethoprim,
1:2 dilution, 10|ig/mL to 19.5 ng/mL

('oliimn 11
E. coli only
(no antibiotic)
E. coli only
(no antibiotic)
E. coli only
(no antibiotic)
E. coli only
(no antibiotic)
E. coli only
(no antibiotic)
E. coli only
(no antibiotic)
E. coli only
(no antibiotic)
E. coli only
(no antibiotic)

i ( olumn 12
Media only
Media only
Media only
Media only
Media only
Media only
Media only
Media only
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strain 90-2380 was added to each well of the plate, except column 12, the media-only
control column.

The plate was incubated overnight at 37°C statically.

Following

incubation, the plate was visually observed for turbidity in each well. The plate was also
assessed spectrophotometrically for absorbance values at 595 nm. The absorbance values
were graphically represented to depict the lowest concentration of antibiotic that inhibited
growth of the organism, as compared to the no-antibiotic control.

4.4.

Growth Curves of E. coli Q157:H7 in 90% MIC Antibiotics
E. coli 0157:H7 strain 90-2380 was grown in stationary culture at 37°C overnight

in MHB. The following day the culture was adjusted with pre-warmed MHB to give an
optical density of 0.2 at 595 nm. This culture was grown for an additional 60 min at 37°C
to achieve log phase of growth. The culture was then centrifuged at 4,000 rpm for 5 min
(IEC Centra) and the pellet was resuspended in MHB media to the same volume as
before centrifugation. The culture was then divided into 10 equal 5-mL aliquots. The
eight antibiotics were added to each of the 5-mL aliquots to yield a final concentration
equivalent to 90% of that antibiotic's MIC. A positive control containing 2.5 |ig/mL of
mitomycin C-induced culture was included as the ninth sample, and the tenth sample was
left uninduced.
Three 200(j.L aliquots from each of these ten tubes were immediately removed
and pipetted in triplicate into a sterile 96-well plate (Corning). The 96-well plate was
inserted into a microplate reader (Tecan, Durham, NC) and maintained in static
conditions at 37°C. Absorbance readings at 595 nm were taken every 5 to 15 min for 6 h

and recorded into an Excel spreadsheet. The data were plotted to determine a growth
curve for E. coli 0157:H7 in the presence of antibiotics at 90% of their MIC level.

4.5.

MTT Cytotoxicity Assay Standards
A standard curve for the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-

tetrazolium bromide) was prepared by seeding vero cells in quadruplicate into each well
of a 96-well plate to give a dilution series. This was achieved in a similar fashion to the
passaging procedure described, except instead of seeding 10,000 cells/well, wells were
seeded at the concentrations outlined in Table 2.2.

Vero cells in each well were

stabilized for 1 h at 37°C in 7% C0 2 (Airgas, Salem, NH) to allow cells to settle and
attach to the microtiter plate. Following the 1 h incubation, 10|xL of MTT salt solution
was added to each well and incubated for 3 h at 37°C in 7% CO2. During this incubation,
viable vero cells converted the yellow MTT salt to insoluble purple formazan crystals.
After incubation, 100 |iL MTT lysing solution was added to each well. This solution
lysed the vero cells and dissolved the fomazan crystals to give a uniform shade of purple,
which was evaluated in a Biorad 3550 spectrophotometer (BioRad, Hercules, CA). The
absorbance data generated was graphically plotted in relation to the seeded number of
vero cells, resulting in a linear equation over a particular concentration of vero cells.
This standardization process allowed for unknown concentrations of vero cells to be
enumerated based on a correlation to this standard.
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Table 2.2. Vero Cell Seeding for MTT Standards.

Coll
0 cells

Col 2
5xl02
cells

Col 3
lxlO3
cells

Col 4
2.5 x 10"
cells

Col 5
5xl03
cells

Col 6
lxlO4
cells

Col 7
2.5 x
104 cells

Col 8
5xl04
cells

Col 9
7.5 x
104 cells

Col 10
lxlO5
cells
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4.6.

Induction of Stx-2 by Antibiotics for MTT Assay
E. coli 0157:H7 strain 90-2380 was grown in static culture overnight in MHB at

37°C. The following day the culture was adjusted with pre-warmed MHB to give an
optical density of 0.2 at 595 nm. This culture was grown for an additional 60 min to
stimulate the cells into log phase growth. This culture was centrifuged at 4,000 rpm for 5
min (IEC Centra), the supernate was discarded, and the pellet was resuspended in the
identical type and volume of media as before centrifugation.

This served to remove

residual toxin from the overnight growth so that only newly-formed toxin would be
assayed. The culture was divided into 10 equal 5-mL aliquots.

Each of the eight

antibiotics was added to each 5-mL aliquot to yield an overall concentration equal to 90%
of that antibiotic's MIC. This value was recorded as the sub-inhibitory concentration
(SIC). A positive control of culture containing 2.5 |J.g/mL mitomycin C to induce DNA
damage to organisms was included, along with a negative control of uninduced bacteria.
The control cultures and the test cultures (grown in the SIC of each antibiotic) were
incubated under static conditions for 24 h at 37°C. Immediately following incubation, the
cultures were centrifuged at 4°C at 4,000 rpm for 10 min to pellet. The supernates were
removed and filtered through a low-protein binding 0.2 iim filter (Pall, East Hills, NY) to
give cell-free preparations. These supernates were stored at -20°C for use in MTT assays.

4.7.

Antibiotic-Induced MTT Assay
Supernates from antibiotic-induced cultures were added in triplicate (10|J,L) to a

100% confluent 96-well plate of vero cells.

Controls (mitomycin C-induced and

uninduced) were also added to the vero cell plate. The plate was incubated at 37°C in 7%

51

CO2 (Airgas) for 72 h. Following the 3-day incubation, 10 |0,L of MTT salt was added to
each supernate-containing well. The plate was incubated for 3 h at 37°C in 7% CO2.
After incubation, 100 |iL of MTT lysing solution was added to each well. This solution
lysed the vero cells and dissolved the fomazan crystals to a uniform shade of purple,
which was then read in a Biorad 3550 spectrophotometer (BioRad) and recorded.

4.8.

Induction of Stx-2 by Antibiotics for Real Time PCR and ELISA
E. coli 0157:H7 was grown as static cultures overnight in MHB at 37°C. The

following day the culture was adjusted with pre-warmed MHB to give an optical density
of 0.2 at 595 nm. This culture was grown for an additional 60 min to stimulate the cells
into log phase growth. This culture was centrifuged at 4,000 rpm for 5 min (IEC Centra)
the supernate was discarded, and the pellet was resuspended in the identical type and
volume of media as before centrifugation. This served to remove residual toxin from the
overnight growth so that only newly-formed toxin would be assayed. The culture was
divided into 10 equal 2-mL aliquots. Each of the eight antibiotics was added to each 2mL aliquot to yield an overall concentration equal to the SIC for each antibiotic. A
positive control culture containing 2.5 |i,g/mL mitomycin C to induce DNA damage to
organisms was included, along with a negative control of uninduced bacteria.

The

control cultures and the test cultures (grown in the SIC of each antibiotic) were incubated
under static conditions for 1 h or 6 h at 37°C. Immediately following incubation, 100 \\L
of each culture was removed to a sterile microcentrifuge tube and retained for RNA
extraction, which was performed immediately.

For the collection of supernates for

ELISA analysis of Stx-2 concentration, the cultures were further incubated for a total of
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24 h post-induction. The 2-mL cultures were then centrifuged at 4°C at 4,000 rpm for 10
min to pellet the bacterial cells. The supernates were removed and filtered through a lowprotein binding 0.2 Jim filter (Pall) to give cell-free preparations. These supernates were
stored at -20°C for use in ELISA assays.

4.9.

RNA Extraction and cDNA Synthesis
Directly following antibiotic induction of the cultures, 500 ^iL of Bacterial RNA

Protect™ (Qiagen, Valencia, CA) was added to each of the 100 \\L aliquots and
incubated at room temperature for 15 min. The tubes were then centrifuged at 5400 rpm
(Beckman, Center Valley, PA) for 5 min. RNA was collected using the Promega SV
Total RNA Isolation System™ kit (Promega, Madison, WI), as follows. The supernates
were discarded and the pellets resuspended in 100 \xL of tris-ethylene diamine tetra acetic
acid (TE) buffer along with 2 \\L of lysozyme stock (20mg/mL,) and incubated at room
temperature for 5 min. The cells were further lysed by the addition of 75 \xL of RNA
Lysis Buffer (Promega), and 350 \\L of RNA dilution buffer (Promega). Nucleic acids
were precipitated by the addition of 200 \xL 95% ethanol (Acros, Morris Plains, NJ).
Each solution was transferred to a separate filter spin column provided in Promega kit
and centrifuged at 10,000rpm for 1 min. The filtrates were discarded and 600 \\L of
RNA wash solution were added to rinse remaining cellular debris from the columns. The
tubes were re-centrifuged at 10,000 rpm for 1 min. DNA in each column was degraded
by the addition of 40 (J.L yellow core buffer (Promega), 5 ixL of 0.09M MnCh (Promega),
and 5 \\L DNase I enzyme (Promega). The DNase mixture was incubated at room
temperature directly on the spin column membranes for 30 min. After incubation, 200|iL
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of DNase stop solution (Promega) was added to the spin columns and centrifuged at
10,000rpm for 1 min. The RNA was washed twice, first with 600 |0,L, then with 250 \xL,
of RNA wash solution (Promega) to remove degraded DNA and residual buffer. The
spin columns were transferred to elution tubes and 100 (iL of nuclease-free water was
added to the membranes. The columns were centrifuged at 10,000 rpm for 1 min to elute
the RNA. The spin columns were removed and discarded, and the eluted RNA was
stored at -20°C for use in cDNA synthesis assays.
The RNA was checked for DNA contamination by PCR. As PCR amplifies DNA
only, this step was included to verify that there was no DNA contaminating the RNA
samples. PCR was run in a thermocycler (Perkin-Elmer GeneAmp, Waltham, MA) with
a 5 min, 94°C denaturation step, followed by 30 cycles of amplication. The amplification
cycles were 94°C for 30 sec, 54°C for 30 sec, 72°C for 30 sec. The PCR run was
terminated with a 7 min elongation step at 72°C. Purified E. coli 0157:H7 strain 90-2380
DNA was used as the positive control. All PCR products were stored at -20°C for
agarose gel electrophoresis purity analysis.
A 2.5% agarose gel was made by melting 1.25 g of agarose (Omnipur, Lawrence,
KS) in 50 mL of lx Tris-acetate-ethylene diamine tetraacetic acid (TAE). The gel
solution was poured into the casting stand and allowed to solidify, during which time the
samples were prepared by mixing 6 |J,L of the template (in this case, the PCR product of
extracted RNA) with 2 |J,L 6x loading buffer (Promega) and 4 |iL d.H 2 0. The solidified
gel was placed into the electrophoresis apparatus (Biorad) and covered with lx TAE.
Samples were loaded into the gel and run at approximately 100 volts (+/- 5 volts) until
two-thirds of the way down the gel. A 1 kb ladder with 100 bp bands (New England
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Biolabs, Ipswich, MA) was run simultaneously for band size comparisons. The gel was
stained in ethidium bromide and visualized in an imaging system (Syngene Bio-Imaging,
Frederick, MD).

Samples that were DNA-free were deemed acceptable for cDNA

synthesis. Any samples found to contain DNA were discarded.
cDNA synthesis was performed using the Superscript HI cDNA synthesis kit™
(Invitrogen, Carlsbad, CA). In thin-walled PCR tubes, 6 (iL of RNA, 1 jj,L of 50 ng/|xL
random hexamers (Invitrogen), and 1 |J,L annealing buffer (Invitrogen) were combined
and collected by a brief, 3-second mini-centrifugation. The tubes were heated for 5 min
at 65°C in a heating block (VWR, Westchester, PA) and immediately placed on ice for 1
min. Following the ice-incubation, 10 |xL of 2x First-strand reaction mix (Invitrogen)
was added to the tube with 2 ^iL of Superscript III/RNase Out enzyme mix (Invitrogen).
The samples were thoroughly mixed and placed in the thermocycler with the following
settings: 10 min at 25°C, 50 min at 50°C, 85°C for 5 min, followed by a 4°C hold period.
cDNA samples were amplified through a second PCR and agarose gel to ensure proper
reverse-transcription of RNA into cDNA was achieved. cDNA samples which amplified
in a PCR reaction were deemed acceptable and were stored at -20°C until for use in Real
Time PCR assays.

4.10.

Quantification of cDNA
cDNA samples were quantified using the Qubit High Sensitivity (HS) DNA

Quantification kit™ (Invitrogen) according to the manufacturer's instructions. In brief,
the 200x concentrated analyzing reagent was diluted 1:200 in the supplied diluent to give
a single strength analyzing reagent. cDNA samples were diluted 1:100 in the analyzing
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reagent and were incubated at room temperature for three min, after which each sample
of cDNA was assayed for fluorescence activity in the Qubit fluorometer.

The

fluorometer was calibrated prior to each use using the kit-supplied standards.

4.11.

cDNA standardization
Antibiotic-induced

cDNA samples were standardized to a

100 ng/mL

concentration using nuclease-free water prior to use in Real Time PCR experiments.
Standardized cDNA samples were stored at -20°C.

4.12.

Real Time Polymerase Chain Reaction
Real Time PCR was performed using an AP 7300 Thermocycler and software

(Applied Biosystems, Carlsbad, CA). PCR was performed using 200 nM of dual-labeled
(FAM/TAMRA) fluorogenic probes (Appendix C), 500 nM of both forward and reverse
primers (Appendix C), and a lx concentration of PCR enhancer (5Prime, Gaithersburg,
MD) and a lx concentration of RealMasterMix with Rox (5Prime). The RealMasterMix
with Rox contains 0.1 U/(iLTaq DNA Polymerase, 12.5 mM magnesium acetate, and 1.0
mM dNTPs. A standard curve was performed with each Real Time PCR experiment, and
each standard curve was constructed using highly-purified PCR product (see Appendix
C) at a final concentration of 100 ng prepared in a 10-fold dilution to give a terminal
concentration of 10 pg.
Real Time PCR data were analyzed using the REST (Relative Expression
Software Tool) program. The PCR efficiency for each Real Time PCR run was entered
into the software program along with the cycle threshold values for each sample. The
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program normalized each value to the supplied data for the serC housekeeping reference
gene and to its PCR efficiency. Once normalized, the treated samples, consisting of the
eight antibiotics and mitomycin C were compared against the untreated sample
(uninduced) for up or down regulation in the genes of interest {stx2, dinD).

4.13.

Enzyme-linked Immunosorbent Assay
ELISA was designed based after a protocol by Moody, 2003 (102). Murine anti-

Stx-2 subunit A (monoclonal IgG H E 10, Toxin Technology, Sarasota, FL) was
employed as the primary antibody. This was diluted 1:250 to give a working stock IgG
preparation in sterile lx PBS. This primary antibody was applied to the ELISA plate and
incubated overnight on a plate rocker to allow the antibody to adhere to the wells of the
microtiter plate.

The following day, plates were drained and each well filled with

blocking buffer containing 5% skim milk and allowed to rock at room temperature for 1 h
to prevent subsequent non-specific binding. The plate was then emptied and rinsed three
times with PBS. A ten-fold dilution series of purified Stx-2 (Toxin Technology) was
applied in triplicate in order to derive a standard curve for the assay. The supertiates to
be tested were also added in separate wells in the plate in triplicate. Any unused wells
were filled with blocking buffer and the entire plate was incubated at room temperature
for 2 h while rocking. The plate was then emptied and rinsed three times with PBS. The
secondary antibody, monoclonal murine antibody specific to Stx-2 subunit A and
conjugated to horseradish peroxidase (Toxin Technology), was added to each well and
incubated at room temperature for 2 h while rocking. After incubation, the wells were
thoroughly washed (five times) with PBS to remove all traces of unbound secondary
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antibody. The horseradish peroxidase chromogenic substrate (2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt, ABTS) solution (Pierce, Rockford,
IL) was added to the wells and incubated for 1 h. The plate was spectrophotometrically
analyzed at 405 nm and the data were recorded.

5.

Results
Statistical significance was determined as described in Appendix B, Section 5.

5.1.

Minimum Inhibitory Concentration (MIC) Assay
The MIC value for each antibiotic was determined to be the lowest concentration

of antibiotic that still inhibited the growth of the E. coli 0157:H7. In all cases, the visual
(Figure 2.1) and spectrophotometric (Figure 2.2) results for the MIC were in agreement.
The sub-inhibitory concentration (SIC) was calculated as 90% of these derived MIC
values (Table 2.3).
MIC values were lowest for the DNA-damaging antibiotics ciprofloxacin and
norfloxacin; a concentration of 31.25 ng/mL was sufficient to inhibit growth of the E.
coli.

Trimethoprim, an inhibitor of thymidine and uridine synthesis, and therefore

involved in blocking the synthesis of DNA, was found to have an MIC value of 156.25
ng/mL.

The same MIC value was calculated for gentamicin, an aminoglycoside.

Polymyxin B, a cell membrane disruptor, required 1.25 |ig/mL to inhibit growth of the
microorganism. Cefotaxime, a beta lactam, and rifampin, an inhibitor of transcription
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A)
Columns 1-10
1
2
3
4
5
6
7
8

^

Cefotaxime,
1:2 dilution, 10 mg/mL to 19.5 |ig/mL
Ciprofloxacin,
1:2 dilution, 1 |ig/mLto 1.95 ng/mL
Chloramphenicol,
1:2 dilution, 100 ng/mL to 195 ng/mL
Gentamicin,
1:2 dilution, 100 [ig/mL to 195 ng/mL
Polymyxin B
1:2 dilution, lO^g/mL to 19.5 ng/mL
Rifampin,
1:2 dilution, 100 ng/mL to 195 ng/mL
Norfloxacin,
1:2 dilution, 1 |0,g/mLto 1.95 ng/mL
Trimethoprim,
1:2 dilution, 10|0,g/mL to 19.5 ng/mL

Column 11 a
£. co// only
(no antibiotic)
E. coli only
(no antibiotic)
E. coli only
(no antibiotic)
E. coli only
(no antibiotic)
E. coli only
(no antibiotic)
E. coli only
(no antibiotic)
E. coli only
(no antibiotic)
E. coli only
(no antibiotic)

Column 12
Media only
Media only
Media only
Media only
Media only
Media only
Media only
Media only

Figure 2.1. MIC Microliter Plate. A) Schematic set up of the MIC microtiter plate.
Each row of the microtiter plate represents an antibiotic to be tested. The first, left-most
column of the microtiter plate is the stock concentration of the antibiotic, and each
subsequent column represents a 2-fold dilution of that antibiotic. Column 11 was the noantibiotic control (PBS only), and Column 12 was the no-is. coli control (PBS only). B)
MIC plates were inspected visually for turbidity (opalescent) in a well, indicating growth.
The lowest concentration of antibiotic that still inhibited growth was defined as the MIC.
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Figure 2.2. MIC Determination By Spectrophotometer. The MIC plate was read at 595nm to determine the
optical density of each well. Each collection of gray bars (solid and hatched) represents the density of growth of the
E. coli in each dilution of antibiotic. The black bars represent growth of the E. coli without antibiotic. The white
bars represent media-only controls. The hatched gray bar represents the MIC value; this is the lowest concentration
of antibiotic that still inhibited growth of the organism. See Table 2.3 for tabulated data.
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Table 2.3. Determined MIC and Calculated SIC for E. coli 0157:H7
Antibiotic

Target

Cefotaxime
Ciprofloxacin
Chloramphenicol

Inhibits peptidoglycan synthesis
Inhibits DNA gyrase
Inhibits peptidyl transferase, 50S
subunit
Prevents formation of initiation
complex with mRNA (30S
subunit), Causes misreading of
mRNA, possible other
mechanisms.
Detergent, interacts with
phospholipids.
Binds and inhibits RNA
polymerase
Inhibits DNA gyrase
Inhibits de novo thymidine and
uridine synthesis.

Gentamicin

PolymyxinB
Rifampin
Norfloxacin
Trimethoprim

5.0 fig/mL
31.25 ng/mL
10 fig/mL

SIC
(90% MIC)
4.5 |ig/mL
28.13 ng/mL
9(ig/mL

156.25 ng/mL

140.63 ng/mL

1.25 |ig/mL

1.13|ig/mL

5 (ig/mL

4.5 fig/mL

31.25 ng/mL
156.25 ng/mL

28.13 ng/mL
140.63 ng/mL

MIC
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processes, both had calculated MIC values of 5|ig/mL. Chloramphenicol was found to
have an MIC value of 10|ig/mL.

5.2.

Growth Curves of E. coli Q157:H7 in Antibiotics
E. coli 0157:H7 strain 90-2380 was grown and induced with antibiotics in a

fashion identical to that described for ELISA supernates and mRNA collection for Real
Time PCR. Following induction, the cultures were measured for absorbance at 595nm
every 5 to 15 min. The data were collected and used to generate a growth curve of the
organism in the presence of the SIC of each antibiotic. As can be seen from Figure 2.3,
no significant differences were detected between the growth of the organism in the SIC of
each antibiotic, and in the uninduced control culture.

5.3.

MTT Cytotoxicity Assay
An MTT cytotoxicity assay was developed to determine the effects on vero cells

of the Stx-2-containing supernates. A standard control curve was developed for the MTT
assay by seeding a 96-well plate with a known dilution of vero cells (without Stx-2) and
comparing it to the absorbance created by those cells at the completion of the MTT test.
The standard curve (Figure 2.4) showed excellent linearity between the number of vero
cells and the absorbance value recorded by spectrophotometer.

The correlation

coefficient for the line was 0.9992.
Once the standard curve had been established for the assay, vero cells were
exposed to the various Stx-2-containing supernates collected from E. coli 0157:H7 strain
90-2380 grown in each of the eight antibiotics.

Data were normalized against the

uninduced control. Supernates from the organism grown in mitomycin C were used as
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-Cefotaxime
-Ciprofloxacin
-Chloramphenicol
-Gentamicin
-PolymyxinB
-Rifampin
-Norfloxacin
—*—Trimethoprim
MitomycinC
^I^Uninduced

150

180

210

360

Minutes

Figure 2.3. Growth Curve of E. coli 0157:H7 strain 90-2380 in SIC-level Antibiotics
Investigated. Note that growth curves of the organism in the antibiotics were similar to
the uninduced controls.

63

5000

10000

15000

20000

30000
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Figure 2.4. MTT Cytotoxicity Assay Standard Curve. Vero cells were seeded at
known number densities and then measured by MTT cytotoxicity assay to develop a
standard curve. Correlation coefficient = 0.9992.
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positive controls while supernates from the organism grown in uninduced MHB were
used as negative controls (Fig 2.5). Supernates collected from E. coli grown with either
DNA-damaging antibiotic, ciprofloxacin or norfloxacin reduced vero cell viability to
70% and 85%, respectively. As predicted, the positive control supernates from growth in
mitomycin C also decreased vero cell viability (75%). The average viability for the vero
cells also declined when grown with supernates from trimethoprim-induced cultures,
though this was not statistically significant. Vero cell viability increased to 125% of the
uninduced control when the supernate from E. coli grown with polymyxin B was used.
Treatment of E. coli with cefotaxime, chloramphenicol, gentamicin, or rifampin did not
significantly alter the vero cell viability compared to the uninduced control.

5.4.

ELISA Analysis of Antibiotic Induced E. coli Q157:H7
Following antibiotic-induction of the E. coli 0157:H7 strain 90-2380 cultures,

supernates were assayed for Stx-2 concentration by ELISA. Dilutions of commercially
obtained Stx-2 (Toxin Technology) were used to construct a standard curve for
comparison (Figure 2.6).

The standard curve showed exceptional linearity with a

correlation coefficient of 0.9932.
Samples of supernates from antibiotic-induced cultures were collected.

All

antibiotic-induced samples were normalized against the uninduced control, and data is
shown as fold-increase in Figure 2.7. As expected, the positive control mitomycin C
increased Stx-2 production by 2-fold compared to the uninduced control. Likewise, the
three antibiotics that act on the DNA of bacterial cells, ciprofloxacin, norfloxacin, and
trimethoprim, all increased Stx-2 by some degree. Ciprofloxacin surpassed the positive
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Figure 2.5. MTT: Cytoxicity of E. coli 0157:H7 Supernates from Antibiotic-induced
Cultures. All data were normalized against the uninduced control (white bar). Data for
cefotaxime, chloramphenicol, gentamicin, rifampin, and trimethoprim (gray bars) show
no significant change from the uninduced sample. Data for ciprofloxacin, norfloxacin
and the positive control mitomycin C (black bars) show significant decreases in vero cell
viability. Polymyxin B (hatched bar) showed a significant increase in viability compared
to the uninduced sample.
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0.35

0.25

0.15

0.05

Figure 2.6. Stx-2 Standard Curve: ELISA. Standard concentrations of commercially
purchased Stx-2 were evaluated in an ELISA to obtain a standard curve. Correlation
coefficient = 0.9932. A separate standard curve was prepared for each ELISA
determination, each of which yielded results similar to this example.
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Figure 2.7. ELISA: Increase in Stx-2 Concentration After 24 h Induction with
Antibiotics. All antibiotic-induced samples were normalized against the uninduced
control (white bar). Data are shown as fold-increase compared to the uninduced sample.
For the antibiotics cefotaxime, chloramphenicol, gentamicin, no significant increase
beyond the uninduced control was noted (gray bars). Ciprofloxacin, norfloxacin,
trimethoprim, and the positive control mitomycin C (black bars) gave significantly higher
values than the uninduced control. Polymyxin B and rifampin (hatched bars) showed
significant decreases as compared to the controls.
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control and increased Stx-2 by 2.25-fold. Stx-2 production by E. coli 0157:H7 increased
to 1.65 times the uninduced control when treated with norfloxacin.

Trimethoprim

increased Stx-2 by 1.3-fold. Both polymyxin B (a cell membrane disruptor) and rifampin
(a transcription inhibitor) decreased Stx-2 production to approximately 0.75% and 0.85%
of the uninduced control. No significant change in Stx-2 production was seen when the
pathogen was grown in the presence of cefotaxime, chloramphenicol, or gentamicin.

5.5.

Real Time PCR Analysis of E. coli Q157;H7 Transcripts
At 1 hour after induction with the various antibiotics, a marked difference in stx2

and dinD expression compared to the uninduced control was noted (Figure 2.8). dinD
expression was increased by 5.7-fold when E. coli was grown with the positive control,
mitomycin C. Norfloxacin and ciprofloxacin also increased dinD expression by 4.0-fold
and 4.8-fold, respectively. These results were expected, as all three agents act on the
DNA of bacterial cells, and dinD is highly expressed in the presence of DNA damage.
Chloramphenicol also increased dinD expression, though to a lesser degree (2.2-fold).
stx2 expression was increased by growth in mitomycin C (1.2-fold), ciprofloxacin (1.6fold), and polymyxin B (3.7-fold). Gentamicin reduced stx2 expression to 0.67-fold of
the uninduced control. At 6 h of antibiotic induction, the profile of dinD and stx2
expression changed slightly, as seen in Figure 2.9. dinD and stx2 expression were both
still upregulated by ciprofloxacin (4.1-fold, 8.5-fold), norfloxacin (2.2-fold, 4.5-fold), and
the positive control mitomycin C (2.6-fold, 5.4-fold). Interestingly, whereas no
significant change in either gene was seen with a 1 h induction with trimethoprim, at 6 h
post-induction, the expression of dinD and stx2 were both increased (1.9-fold, 2.4-fold).
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• Stx2
• DinD
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Figure 2.8. stx2 and dinD Expression by Real Time PCR after 1 h Induction with
Antibiotics. At one h post-induction, stx2 expression was upregulated by growth in
ciprofloxacin, polymyxin B, and mitomycin C, while stx2 expression was downregulated
in gentamicin.
dinD expression was upregulated by growth in ciprofloxacin,
chloramphenicol, norfloxacin, and the positive control, mitomycin C.
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Figure 2.9. sfo2 and dinD Expression by Real Time PCR after 6 h Induction with
Antibiotics. At 6 h post-induction, stx2 expression was upregulated by growth in
ciprofloxacin, gentamicin, norfloxacin, trimethoprim and mitomycin C. stx2 expression
was downregulated in polymyxin B, rifampin. dinD expression was upregulated by
growth in ciprofloxacin, norfloxacin, trimethoprim, and mitomycin C.
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Gentamicin, which was found to reduce stx2 expression at 1 h actually increased stx2
expression to 2.6-fold greater than the uninduced control after 6 h of induction. stx2
expression was downregulated by growth in polymyxin B and in rifampin, by 0.65 and
0.83-fold, respectively. Table 2.4 summarizes the results of the MTT cytotoxicity assay,
the ELIS A studies, and q-PCR studies at both 1 and 6 h antibiotic induction.

6.

Discussion
Despite the major clinical problems associated with the disease, there is currently

no accepted treatment for patients infected E. coli 0157:H7 (132). Retrospective studies
have shown that treatment with antibiotics often worsened the course of disease,
potentially leading to the deadly complication HUS (86, 171). Studies have reported that
the principal virulence factor for this pathogen, the toxin Stx-2, is produced in greater
concentrations when treated with DNA-damaging antibiotics (57, 74). It was originally
hypothesized for the present studies that Stx-2 production and stx2 expression would be
increased when E. coli 0157:H7 strain 90-2380 was grown in the SIC of each DNAdamaging antibiotic. Although some variability was noted, the data from these assays
confirmed the validity of this hypothesis. Because the location of the stx2 gene is within
the phage structural genes, stx2 is co-expressed when these phage genes switch from
lysogeny to lysis. It was thought that DNA-damaging antibiotics would "turn on" the
SOS DNA repair system, which would in turn activate the RecA protein. Activated
RecA normally recognizes and cleaves the protein LexA, but because of the structural
similarity of LexA to the 933-W repressor cl, this repressor is also degraded by RecA
(104, 164). These studies have shown that stx2 was indeed upregulated when this
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toxigenic organism was grown in the DNA-damaging antibiotics, ciprofloxacin,
norfloxacin, and trimethoprim, and that this upregulation coincided with an upregulation
in the DNA damage inducible gene, dinD. Likewise, an increase in Stx-2 production was
seen at 24 h post-induction with the same three antibiotics (ciprofloxacin, norfloxacin and
trimethoprim), as assayed by ELISA.

These data dovetailed closely with MTT

cytotoxicity results, which showed an increase in vero cell death, presumably due to an
increase in Stx-2, when vero cells were subjected to supernates from E. coli 0157:H7
grown in either ciprofloxacin or norfloxacin. Supernates collected from E. coli 0157:H7
trimethoprim induction also lowered vero cell viability, though not to a significant degree
more than the uninduced control. Ciprofloxacin and norfloxacin are fluoroquinolones,
and their mode of action is to bind to DNA gyrase and topoisomerase IV (59, 112).
Through this binding, this class of antibiotics induces DNA breakages, which in turn
induce the SOS DNA repair system in the microorganism (74). Trimethoprim affects
DNA in a more indirect manner by binding to dihydrofolate reductase and inhibiting the
formation of folic acid, a necessary precursor to nucleic acid bases (17).

Although

trimethoprim does not directly induce DNA damage, it has been shown to be a potent
inducer of the SOS response (79). Growth of E. coli 0157:H7 strain 90-2380 in any of
the three DNA-damaging, SOS response-inducing antibiotics tested led to an increase in
stx2 gene expression and Stx-2 production. These studies confirmed the hypothesis that
stx2 expression and Stx-2 production by E. coli 0157:H7 were increased by DNA
damage and the SOS response.
Unexpectedly, the 6 h treatment with gentamicin caused an upregulation in stx2
expression by 2.67-fold; however this did not correlate with an increase in dinD

74

expression and these results were not confirmed in the ELISA or MTT cytotoxicity
assays. In fact, gentamicin was seen to significantly decrease stx2 expression at 1 h by
0.67-fold. It was not clear why gentamicin, an antibiotic that acts on the 30S ribosome to
block the binding of formylmethyl transfer RNA to prevent the formation of initiation
complexes at the early stage in bacterial protein synthesis (55), thus leading to nonsense
peptides, caused an upregulation in stx2 at 6 h. However, the mode of action of the
aminoglycosides such as gentamicin is complex, and it is possible that these observed
results are due to other ill-defined action of the antibiotic on the pathogen. Indeed,
gentamicin is known to be both bacteriostatic via the protein synthesis processes it
induces, yet it has also been shown to be bactericidal by mechanisms not well defined. It
is thought that gentamicin can increase bacterial membrane leakage, leading to cell death
(66, 67). This additional mode of action may offer an explanation for the upregulation of
stx2 seen at 6 h post-induction. As with gentamicin at 6 h, polymyxin B increased stx2
expression at 1 h post induction but this was not seen at 6-h post induction. Like
gentamicin, polymyxin B disrupts cell membranes through ionic interactions (137). It is
possible that the disruption of the bacterial cell membranes caused an upregulation in
stx2.

For polymyxin B, this upregulation was seen at 1 h post induction, yet for

gentamicin, this upregulation was only seen in the 6 h post induction experiments.
Gentamicin may require more time (6 h as opposed to 1 h) for this upregulation in stx2 to
be detectable. With increased cell membrane permeability would come an increase in
diffusible bacterial signal molecules released by quorum sensing, which would then be
better able to pass into the E. coli cells. Quorum sensing has been shown to be an
upregulator of the several virulence genes in E. coli 0157:H7, including stx2 (3, 72, 147,
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148). Further research into the effect of cell membrane disrupters on stx2 and on the
uptake of quorum sensing molecules is needed to fully elucidate this upregulation in stx2.
Although gentamicin at 6 h post-induction and polymyxin B at 1 h post-induction
increased expression of stx2, these antibiotics did not ultimately result in an increase in
Stx-2, as shown by ELISA and MTT cytotoxicity assay. Studies on pertussis toxin,
another AB5 toxin with some similarities to Stx-2, have shown that polymyxin B
inhibited the release of the pertussis toxin from the Bordatella pertussis cells (27).
Pertussis toxin is assembled in the periplasm of the cell, and when polymyxin B is
present, assembly and release of the toxin is inhibited (27). It is possible that a similar
mechanism is engaged in E. coli 0157:H7, however, the means by which Stx-2
molecules are secreted from the microbial cell are not fully elucidated (121). Despite the
upregulation of stx2, these agents (gentamicin and polymyxin B) did not increase Stx-2
production, and in the case of polymyxin B, actually decreased Stx-2 production overall.
Of the eight antibiotics representing various classes of antibiotic groupings
evaluated for their effects on stx2 expression and Stx-2 production, only rifampin
consistently caused less stx2 expression and less Stx-2 production by E. coli 0157:H7.
Rifampin binds to DNA-dependent RNA polymerase and inhibits transcription by
blocking the synthesis of mRNA. Rifampin was able to reduce stx2 expression by 0.83fold at 6 h post-induction, although reduction at 1 h post-induction was not significant.
Stx-2 release from the E. coli 0157:H7 cells was also reduced to 0.88-fold that of the
uninduced control. Though not significant due to variations between trials, rifampin also
increased vero cell survival to 110%, of the uninduced culture. In a study by Ochoa, et.
Al (109), a related antibiotic, rifaximin was shown to not induce Stx-2 production or
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phage release by E. coli 0157:H7. As the authors point out, in E. coli 0157:H7, sigma
factor 70 (o70) and the antiterminator Q are involved in the expression of the lytic cycle
of the phage; they allow the RNA polymerase to read-through a terminator, thereby
allowing transcription of downstream genes, including stx.

Rifampin and rifaximin

inhibit a 70 action (109), halting the transcription of stx, and this is likely the reason why
stx2 expression and Stx-2 production were diminished when E. coli was grown in
rifampin.

Currently, antibiotic therapy for treating E. coli 0157:H7 infections is

controversial due to possible exacerbation of disease resulting from increased output of
Stx-2 (74, 132). However, these studies have shown that stx2 expression and Stx-2
production are reduced by growth in rifampin compared to no antibiotic treatment, and
therefore this antibiotic should not exacerbate disease by an increase in Stx-2. In a
patient with an E. coli 0157:H7 infection, rifampin may reduce pathogen numbers
without an increase in Stx-2 release, which is ultimately the goal of antibiotic treatment.
Due to the relative ease with which microorganisms develop resistance to rifampin, this
could prove problematic. However, these studies also showed no significant change in
stx2 expression or Stx-2 release when E. coli 0157:H7 was grown in SICs of cefotaxime
(a P-lactam). Synergy has been shown between rifampin and P-lactam antibiotics for
treating difficult, resistant infections, such as those caused by Pseudomonas aeruginosa
(41), Stenotrophomonas maltophilia (24), and methicillin-resistant Staphyloccoccus
aureus (15, 41). Perhaps combined therapy of rifampin and a newer p-lactam may prove
effective for treatment in E. coli 0157:H7 infections. It should be noted that not all
antibiotics should be discounted as treatments for these infections, as not all antibiotic
classes have been demonstrated to cause an increase in Stx-2.
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CHAPTER 3

LACTOBACILLI AND THEIR EFFECT ON
THE PRODUCTION OF STX-2 BY ESCHERICHIA COLIO\51:Wl

1.

Abstract
Previous research has shown that animals co-colonized with both E. coli 0157:H7

and probiotics including various Lactobacillus species, had less severe courses of disease
with decreased concentrations of Stx-2. Likewise, related studies have shown that other
E. coli 0157:H7 virulence factors such as attaching and effacing lesions were reduced by
co-cultivation with various lactobacilli, and that this reduction was not simply due to
secreted molecules by the lactobacilli. In the present study, it was hypothesized that
growth of the E. coli 0157:H7 in co-culture with Lactobacillus casei or Lactobacillus
plantarum would reduce Stx-2 production and stx2 expression through direct cell-to-cell
contact of the pathogen with the probiotic. It was thought that this reduction in virulence
would be seen only when the E. coli and the lactobacilli were present in co-culture, and
not when the pathogen was exposed to cell-free supernates from lactobacilli cultures.
Results have indicated that indeed, Stx-2 production is reduced by direct co-culture with
lactobacilli, but that reduction in Stx-2 was also caused in part by the production of
organic acids by the lactobacilli.
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2.

Introduction
Due to the lack of conventional antimicrobial therapies for E. coli 0157:H7

infections, scientists and physicians have looked to novel therapeutic treatments,
including probiotic microbes. Probiotics are beneficial microbes that are ingested as
homeopathic medicines or through particular food products, such as yogurts, kefir, and
cheese (28, 45, 143, 150). The role of normal microbial flora (NMF) and probiotic
microbes in the fight against pathogens is a rapidly-expanding chapter of microbiology
and infectious diseases. Beneficial gut microbes aid in digestion, produce vitamins, and
stimulate the immune system. Development of lymphocytes, particularly in the gutassociated lymphoid tissue (GALT), relies heavily on the presence of NMF (143, 135).
Gnotobiotic animals, animals that possess no microorganisms whatsoever, display a
much reduced immune system when left unchallenged by NMF (143).

L. casei

specifically has been shown to increase mucus-associated innate immunity in gnotobiotic
mice (90).

Probiotics have also been shown to promote gastrointestinal health by

regulating cytokines, increasing the production of immunoglobulin A (IgA), and
tightening intracellular junctions to inhibit pathogenic bacterial invasion. In this manner,
probiotics act in a passive way to provide defense against pathogenic organisms by
nutrient and space competition (143).
Probiotics can also play a more active role in human intestinal health by reducing
the numbers of pathogenic organisms, and through attenuation of virulence of these
harmful organisms (31). Sherman, et. al in 2005 showed that Lactobacillus acidophilus,
L. casei, and L. plantarum reduced the shedding of enterohemorrhagic E. coli (EHEC) by
cattle, sheep, and rabbits (142). The authors proposed that this reduction in pathogen
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shedding was due to a lowered pH in the guts of these animals because of lactic acid
production by the probiotic organisms. However, upon closer inspection it was seen that
the lactobacilli appeared to prevent virulence factor production in these animal models,
with the result of reducing the amount of attaching and effacing lesions noted on the
intestinal surfaces. This reduction required cell-to-cell contact by the lactobacilli, and
was not merely a passive, pH-related response (142).
In a study by Ogawa et. al (110), cultures of L. casei were fed to infant rabbits on
the day of their birth. After allowing three days for colonization, the infant rabbits were
fed shiga toxin-producing E. coli (STEC). The severity of disease was rated as "severe"
in 77% of rabbits that were not pre-colonized with L. casei, whereas it was rated "severe"
only in 16% of those rabbits that did receive L. casei on the day of their birth. Likewise,
in the untreated group only 9% were rated as having no symptoms or "slight" disease,
whereas in the L. casei-treated group, 68% had no or "slight" disease. This indicated that
L. casei reduced the severity of STEC disease. The concentration of Stx-2 was reduced
by more than 50% in the cecum and colon of rabbits that received the L. casei treatment,
and histopathology showed less vacuolation, exfoliation and necrosis of gut epithelial
cells (110).
In the present study, E. coli 0157:H7 strain 90-2380 was grown in the presence of
either L. casei or L. plantarum as probiotics prepared in ratios of 100:1, 1:1, and 1:100 of
E. coli to probiotic. Control co-cultures contained only E. coli 0157:H7 with sterile
media substituting for the corresponding volume of probiotic.

The stx2 gene was

measured for activity with and without the lactobacilli co-culture using q-PCR. Stx-2
production was measured using ELISA and MTT cytotoxicity studies in vero cells.
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Growth competition assays were employed to determine the extent that E. coli 0157:H7
numbers are affected by co-culture with the two species of Lactobacillus.

3.

Hypothesis
It was hypothesized that co-cultivation of E. coli 0157:H7 with L. plantarum or

L. casei would reduce the expression of the stx2 gene, and would also reduce the
production of Stx-2. These reductions were thought to be due to direct cell-to-cell
contact of the pathogen with the probiotic, and that no reduction in stx2 expression or
Stx-2 production would be seen if the E. coli 0157:H7 were grown with cell-free
supernatant fluid collected from the probiotic cultures.

4.

Materials and Methods
Media and reagent preparations are provided in detail in Appendix A.

4.1.

Bacterial Cultivation
The E. coli 0157:H7 strain 90-2380 stock culture was maintained as described in

Appendix B.

Lactobacillus plantarum and Lactobacillus casei were acquired from

Robert Mooney at the University of New Hampshire culture collection. Lactobacilli
cultures were maintained similarly to E. coli cultures but were grown and stored on
deMan-Rogosa-Sharpe (MRS) media. E. coli and lactobacilli cultures for co-culture
experiments were grown in brain-heart infusion broth (BHIB) under static conditions at
37°C.

4.2.

Vero Cell Growth and Maintenance
African green monkey kidney (vero) cells were acquired and maintained as

described in Appendix B. Vero cells were prepared for use in cytotoxicity studies as
outlined in Chapter 2, section 4.2.

In brief, vero cells were grown to log-phase

confluency in a T25 flask and were then harvested and re-seeded into a 96-well plate at a
concentration of 10,000 cells/well.

4.3.

MTT Cytotoxicity Assay Standards
A standard curve for the MTT assay was constructed as outlined in Chapter 2,

section 4.5. This standardization process allowed for unknown concentrations of vero
cells to be enumerated based on a correlation to this standard.

4.4.

Growth of Lactobacilli and E. coli Q157;H7 Co-cultures for Growth
Competitions
E. coli 0157:H7 strain 90-2380 and L. plantarum and L. casei cultures were

grown at 37°C in static culture in individual tubes overnight in BHD3. Cultures were
standardized to an OD600 of 0.2 in pre-warmed BHIB. These were then grown for 1 h to
stimulate the cells into log phase growth. Cultures were centrifuged at 4,000 rpm for 5
min (IEC Centra) and the pellets resuspended in similar media and volume as before
centrifugation. The cultures of E. coli and each of the lactobacilli were combined in the
specific ratios outlined in Table 3.1, and the mixtures were incubated at 37°C for 24 h.
Separate cultures of each of the lactobacilli and the E. coli were inoculated with prewarmed media and incubated to serve as controls. Following incubation, all cultures
were plated in triplicate onto eosin methylene blue (EMB) agar plates to select for the
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Table 3.1. Co-culture Ratios of Lactobacilli to E. coli 0157:H7
Sample

E. coli 0157:H7

L. casei

Media

100:1 E. coli: L. casei

1980|iL

20^iL

—

1:1 E. coli: L. casei

lOOOjiL

1000|iL

—

20uL

1980ML

—

100:1 E. coli control

1980uL

—

20|xL

\:\E. coli control

lOOOuL

—

1000HL

20uL

—

1980[iL

/:. coli 0157:117

L. plantarum

Media

100:1 E. coli: L. plantarum

1980uL

20jaL

—

1:1 E. coli: L. plantarum

1000nL

1000|aL

—

20[±L

1980|iL

—

100:1 E. coli control

1980uL

~

20|xL

1:1 E. coli control

lOOOuL

—

lOOO^L

20uL

—

1980|lL

1:100 E. coli: L. casei

1:100 E.coli control
Sample
i

1:100 E. coli: L. plantarum

1:100 £•. coli control

E. coli 0157:H7. Colonies were enumerated to compare the number of colony forming
units (CFU) of E. coli 0157:H7 that were present after growth in the presence or absence
of the lactobacilli.

4.5.

Growth of Lactobacilli and E. coli Q157;H7 Co-cultures for MTT Assay
E. coli 0157:H7 strain 90-2380 and L. plantarum and L. casei cultures were

grown and prepared identically to that outlined in section 4.4 above and combined in the
ratios shown in Table 3.1 (previous page). Co-cultures were incubated at 37°C for 24 h,
and following incubation the cultures were centrifuged at 4,000 rpm for 10 min at 4°C to
pellet the cells. The supernates were removed and sterile filtered through a low-protein
binding 0.2|jm filter (Pall). Sterile cell-free supernates were stored at -20°C for use in
MTT assays.

4.6.

Co-cultures MTT Assay
Supernates (10|iL) from probiotic and E. coli co-cultures were added in triplicate

to a confluent vero cell monolayer in 96-well plates. Controls of lactobacilli-only and E.
coli-only cell-free culture filtrates were also added to the vero cell monolayers. Plates
were incubated at 37°C in 7% CO2 for 72 h. Following the 3 day incubation, an MTT
assay was performed on these vero cells as described in Chapter 2, section 4.7. This
assay determined the extent of vero cell killing when subjected to Stx-2-containing
supernate.
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4.7.

Growth of Lactobacillus and E. coli Q157:H7 Co-cultures for Real Time PCR
and ELISA
Co-cultures of E. coli 0157:H7 with each lactobacilli species were prepared

exactly as described in the previous section and in the same ratios as seen in Table 3.1.
Immediately following the 3 h co-culture incubation period,

IOOJJL

of each co-culture

was removed to a sterile microfuge tube and retained for immediate RNA extraction.
The remaining 2 mL cultures were incubated at 37°C for a total of 24 hours, after which
time they were centrifuged at 4°C at 4,000rpm for 10 min to pellet the cells. The
supernates were removed and sterile filtered through a low-protein binding 0.2|0.m filter
(Pall). Sterile cell-free supernates were stored at -20°C for use in ELISA assays.

4.8.

Growth of E. coli Q157:H7 with Lactobacilli Supernates, Organic and
Inorganic Acids
Cultures of E. coli 0157:H7 strain 90-2380, L. casei, and L. plantarum were

grown overnight in BHIB as described in sections 4.5-4.7. The lactobacilli cultures were
centrifuged at 7,500 rpm (Beckman) to pellet the cells. The supernatant fluids were
collected and filtered through a low protein binding membrane (0.2 jam) and retained. In
this experiment, unlike previous experiments in these studies, the lactobacilli cells were
discarded. The pH of each lactobacilli supernate was measured and recorded to be pH
4.5. BHIB aliquots were lowered to pH 4.5 using either lactic acid, acetic acid or
hydrochloric acid. The E. coli 0157:H7 culture was subsequently standardized to an
OD600 of 0.2 and incubated at 37°C for an additional 1 h. The standardized culture of E.
coli 0157:H7 was combined 1:1 with either lactobacilli supernate or an acidified
medium, as defined in Table 3.2, and incubated at 37°C for 24 h. Following incubation,
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Table 3.2. E. coli 0157:H7 Induction by Lactobacilli Supernates

Sample

/:. coli 0157:117 Induced W ith:

A

L. plantarum cell-free supernate, pH 4.5 (in BHIB)

B

L. casei cell-free supernate, pH 4.5 (in BHIB)

C

BHIB control

D

BHIB, pH 4.5 with acetic acid

E

BHIB, pH 4.5 with lactic acid

F

BHIB, pH 4.5 with HC1
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all the E. coli cultures were sterile filtered and the supernates retained for analysis by
ELISA.

4.9.

RNA Extraction and cDNA Synthesis
Directly following induction of the cultures, Bacterial RNA protect (Qiagen) was

added to each aliquot of co-culture to prevent further expression of genes, and to prevent
degradation of the mRNA present. RNA was isolated in the same manner as described in
Chapter 2, section 4.9. The RNA was checked for DNA contamination by PCR as
described, and samples containing DNA were discarded.
cDNA synthesis was performed using the Superscript HI cDNA synthesis kit
(Invitrogen) exactly as described in Chapter 2, section 4.9.

cDNA samples which

amplified in a PCR reaction were deemed acceptable and were stored at -20°C until their
use in Real Time PCR.

4.10.

Quantification of cDNA
cDNA samples were quantified using the Qubit (Invitrogen) High Sensitivity

(HS) DNA quantification kit™, according to the manufacturer's instructions. A brief
description of this process is outlined in Chapter 2, section 4.10.

4.11.

cDNA standardization

Co-culture-induced cDNA samples were standardized to a 50 ng/mL concentration using
nuclease-free water prior to use in Real Time PCR experiments. Standardized cDNA
samples were stored at -20°C.
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4.12.

Real Time Polymerase Chain Reaction
Real Time PCR was performed using an Applied Biosystems 7300 Thermocycler

and software, as described in Chapter 2, section 4.12.

Primers and dual-labeled

fluorescent probes were designed to specifically amplify the target gene, stx2, and the
housekeeping gene, serC, within E. coli 0157:H7 without any nonspecific amplification
of lactobacilli genes. These primers and probes are listed in Appendix C. Primers and
probes were tested before this experimentation to be sure that no cross-amplification
occurred when lactobacilli DNA was used as the template for a PCR reaction.

4.13.

Enzyme-linked Immunosorbent Assay
The ELISA was designed based on a protocol by Krishna Moody (102), and was

conducted as described in Chapter 2, section 4.13.

5.

Results
Statistical significance was determined as described in Appendix B, Section 5.

5.1.

E. coli Q157:H7 and Lactobacilli Co-culture Growth Competitions
E. coli 0157:H7 strain 90-2380 was cultured together with either L. plantarum or

L. casei in a ratio of 100:1, 1:1 or 1:100 to determine the effect of co-culture with
lactobacilli on the growth of E. coli 0157:H7.
A dose-dependent response was seen in the recovery of E. coli 0157:H7 when
grown with varying amounts of L. casei. An approximately 2.5-log reduction in E. coli
0157:H7 numbers were seen when grown in a ratio of 1:100 L. casei, and a 2-log
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reduction was seen when grown in a 1:1 ratio. A 1-log reduction in the amount of E. coli
0157:H7 was seen when grown in a 100:1 ratio with L. casei. These data are represented
graphically in Figure 3.1.
Similar inhibition of E. coli 0157:H7 recovery was noted with L. plantarum cocultures (Figure 3.2). A slightly greater than 2-fold reduction in E. coli 0157:H7 was
seen when grown in a 1:100 ratio with L. plantarum, and a 2-fold reduction was seen
with a 1:1 ratio. This reduction was not as pronounced with approximately a 0.75-log
reduction in E. coli 0157:H7, when it outnumbered the L. plantarum in a ratio of 100:1.

5.2.

MTT Cytotoxicity Assay
An MTT cytotoxicty assay was employed to measure the effect of Stx-2-

containing supernates on vero cells. The MTT assay was standardized by seeding a 96well plate with a set number of vero cells (without Stx-2) and calculating the cell
viability. A standard curve was established, as shown in Chapter 2, Figure 2.4.
Vero cells were subjected to various Stx-2-containing supernates collected from
E. coli 0157:H7 grown in co-culture with either L. casei or L. plantarum. As depicted in
Figures 3.3 and 3.4, co-culture of the E. coli 0157:H7 with L. casei or L. plantarum in a
ratio of 1:100 or 1:1 significantly increased vero cell survival compared to the controls
(supernates from E. coli 0157:H7 grown without the lactobacilli).

When E. coli

0157:H7 outnumbered the lactobacilli in a ratio of 100:1, there was not a significant
difference in vero cell survival with this superaate compared to its corresponding control
of E. coli only.
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Figure 3.1. The Effect of L. casei on the Growth of E. coli 0157:H7.

^M Black bars = 1:100 E. coli to L. casei and corresponding control
EZHZ3 Gray bars = 1:1 E. coli to L. casei and corresponding control
1

I White bars = 100: 1 E. coli to L. casei and corresponding control

Note that less E. coli was recovered from those cultures grown with L. casei than those
grown in pure culture, and this reduction was dose-dependent on the amount of L. casei
present in each co-culture.
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Figure 3.2. The Effect of L. plantarum on the Growth of E. coli 0157:H7.
HH Black bars = 1:100 E. coli to L. plantarum and corresponding control
E D Gray bars = 1:1 E. coli to L. plantarum and corresponding control
White bars = 100: 1 E. coli to L. plantarum and corresponding control

As with the L. casei, less E. coli was recovered from those cultures grown with L.
plantarum than those grown in pure culture. The dose-dependent fashion of this growth
inhibition was seen with both species of Lactobacillus.
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Figure 3.3. MTT Cytotoxicity Results: Co-Culture Induction with L. casei.
Hi

Black bars = 1:100 E. coli to L. casei compared to corresponding control

L U Gray bars = 1:1 E. coli to L. casei compared to corresponding control
I

1 White bars = 100: 1 E. coli to L. casei compared to corresponding control

Results are displayed as a percentage of remaining vero cells when subjected to
supernates from co-cultures compared to supernates from the controls (no L. casei). In a
ratio of 1:100 or 1:1 of E. coli to L. casei, the supernates from L. casd-containing
cultures significantly increased vero cell survival compared to the supernates from E. coli
control cultures.
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180
* = p < 0.05
»» = p < 0.005
* * * = p < 0.0005

1:100 E. coli : L. plantarum

1:1 E. coli : L. plantarum

100: 1 E. coli : L. plantarum

Figure 3.4. MTT Cytotoxicity Results: Co-Culture Induction with L. plantarum.
I H Black bars = 1:100 E. coli to L. plantarum compared to corresponding control
Gray bars =\:\ E. coli to L. plantarum compared to corresponding control
I—I White bars = 100: 1 E. coli to L. plantarum compared to corresponding control
In this figure, results are displayed as a percentage of remaining vero cells when
subjected to supernates from co-cultures compared to supernates from the controls (no L.
plantarum). As with L. casei, in a ratio of 1:100 or 1:1 of E. coli to L. plantarum, the
supernates from L. plantarum-containing cultures significantly increased vero cell
survival compared to the supernates from E. coli control cultures.
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5.3.

ELISA Analysis of E. coli Q157;H7 and Lactobacilli Co-Cultures.
Dilutions of commercially prepared Stx-2 were used to construct a standard curve

for comparison in ELISA analysis, as seen in Chapter 2, Figure 2.6. This standard curve
provided a linear relationship between |ig of Stx-2 and absorbance.
Supernates were collected from co-cultures of E. coli 0157:H7 grown with either
L. casei or L. plantarum and assayed for Stx-2 concentration by ELISA. In a ratio of
1:100 (E. coli: L. casei), L. casei significantly reduced the production of Stx-2 by E. coli
0157:H7 when compared to the control. Approximately 5 |ig of Stx-2 was produced
when co-cultured with the L. casei, compared to 14 |ig in the control culture. In a 1:1
ratio, a smaller, but still significant, reduction of Stx-2 production was seen. When the
pathogen outnumbered the L. casei in a ratio of 100:1, there was not a significant
difference in Stx-2 production compared to the control. Figure 3.5 depicts the absolute
concentrations of Stx-2 (|ig) produced for each of the co-cultures and their controls.
Figure 3.6 represents the same data, but portrays the percentage of Stx-2 in the cocultures as compared to the controls. In this figure, it is clear that the reduction of Stx-2
by the various amounts of L. casei occur in a dose-dependent manner. The concentration
of Stx-2 was reduced to 37%, 67%, and 87% (not significant) of the corresponding
controls for 1:100, 1:1 and 100:1 ratios, respectively.
L. plantarum exerted similar pressure on E. coli 0157:H7 and its production of
Stx-2, as seen in Figure 3.7. The 1:100 ratio co-culture of L. plantarum reduced Stx-2
concentration from 16|ig to 3|_ig.

The 1:1 ratio also significantly reduced Stx-2

production, from 17|ig to 8.5|ig. When the E. coli was in a 100:1 ratio with the L.
plantarum, no change in Stx-2 production was detectable.

Figure 3.8 depicts the
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* = p < 0.05
* * = p < 0.005
* * * = P < 0.0005
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1:100 E. coli
control

1:1 E. coli :
L. casei

1:1 E. coli
control

100:1 E. coli
L. casei

100:1 E. coli
control

Figure 3.5. ELISA: The Effect of L. casei on the Production of Stx-2 by E. coli
0157:H7. In this figure, Stx-2 concentration from co-cultures are compared to pure
culture E. coli Stx-2 production. Note that L. casei exerted a dose-dependent effect on the
production of Stx-2 by E. coli 0157:H7.
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Figure 3.6. ELISA: The Effect of L. casei on the Production of Stx-2 by E. coli
0157:H7. Co-culture concentrations of Stx-2 are normalized against their corresponding
controls. Results are displayed as a percentage of Stx-2 in co-cultures compared to the
controls (no L. casei). In a ratio of 1:100 or 1:1 of E. coli to L. casei, the L. casei
significantly reduced Stx-2 production by E. coli 0157:H7. No significant change was
detected at a ratio of 100:1.
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Figure 3.7. ELISA: The Effect of L. plantarum on the Production of Stx-2 by E. coli
0157:H7. In this figure, Stx-2 concentration from co-cultures is compared to pure
culture E. coli Stx-2 production. Note that L. plantarum exerted a dose-dependent effect
on the production of Stx-2 by E. coli 0157:H7.
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Figure 3.8. ELISA: The Effect of L. plantarum on the Production of Stx-2 by E. coli
0157:H7. Results are displayed as a percentage of Stx-2 in co-cultures compared to the
controls (no L. plantarum). As seen with L. casei, a ratio of 1:100 or 1:1 of E. coli to L.
plantarum, the L. plantarum significantly reduced Stx-2 production by E. coli 0157:H7.
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percentage of Stx-2 in the co-cultures compared to the control in these ELISA analyses.
Stx-2 was reduced by 21% in the 1:100 co-culture, 49% in the 1:1 co-culture, and 98% in
the 100:1 co-culture. As with the L. casei, the reduction in Stx-2 was dependent on the
concentration of L. plantarum present in each co-culture.

5.4.

ELISA Analysis of E. coli Q157:H7 Supernates from Cultures Grown with
Lactobacilli Supernates or Acidified Media
Lactobacilli supernates and media that was acidified to pH 4.5 by an organic acid

(acetic or lactic acid) significantly reduced the production of Stx-2 by E. coli 0157:H7.
However, media that was acidified to the same pH but with hydrochloric acid, an
inorganic acid, caused no significant change in Stx-2 production.

Absolute

concentrations of Stx-2 are shown in Figure 3.9. The control culture of E. coli 0157:H7
produced just fewer than 16|ig of Stx-2. The cultures of E. coli 0157:H7 when grown
with L. plantarum supernate, L. casei supernate, acetic acid-containing media, and lactic
acid-containing media all produced approximately 12|j.g of Stx-2. Figure 3.10 depicts the
concentration of each test sample as a percentage compared against the control. A
significant reduction to 70-80% of the control was seen for all conditions except
hydrochloric acid-containing media.

5.5.

Real Time PCR Analysis of E. coli Q157;H7 Transcripts.
The expression of the stx2 gene in E. coli 0157:H7 was significantly reduced

when grown in co-culture with L. casei and L. plantarum in a ratio of 1:100 or 1:1.
Growth of the pathogen with either lactobacilli species in a ratio of 100:1 did not
significantly alter stx2 expression. As shown in Figure 3.11, the 1:100 ratio of E. coli to

99

* =p<0.05
* * = p < 0.005
* * * = P < 0.0005

**

^^^^H
^^^^^H

#*

•
•I
II
I

^^^^^^H

*;:

• - '

, • ; •

,-

.

> • ;

" • • •

••••

•'-#
L. plantarum
Supernate

L. casei
Supernate

No Supernate

Acetic Acid
(pH 4.5)

Lactic Acid
(pH 4.5)

Hydrochloric Acid
(pH 4.5)

Figure 3.9. ELISA: The Effect of Lactobacilli Supernates or Acidified Media on the
Production of Stx-2 by E. coli 0157:H7. E. coli 0157:H7 was grown with lactobacilli
supernate or acidified BHIB, and Stx-2 concentration was assayed by ELISA. Both
lactobacilli supernates and both organic acids (acetic acid and lactic acid) significantly
reduced Stx-2 production by E. coli 0157:H7. However, hydrochloric acid, an inorganic
acid, did not affect the production of Stx-2.
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Figure 3.10. ELISA: The Effect of Lactobacilli Supernates or Acidified Media on the
Production of Stx-2 by E. coli 0157:H7. Data are depicted as a percent Stx-2
compared to the control (E. coli grown without supernate or acidified media). Growth of
E. coli 0157:H7 with lactobacilli supernate, acetic acid, or lactic acid led to a 70-80%
reduction in Stx-2 production compared to the control.
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Figure 3.11. Real Time PCR Analysis of E. coli 0157:H7 and L. casei Co-Cultures.
Note that both the 1:100 and 1:1 E. coli to L. casei ratio and the 1:100 E. coli to L. casei
culture (solid gray bar, right) significantly reduced stx2 transcripts compared to the E.
coli only controls.
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L. casei decreased stx2 expression to 29% of the control. The 1:1 ratio reduced stx2
expression to 40% of the control. L. plantarum co-cultures with E. coli 0157:H7 also
reduced stx2 expression, though not to the degree that L. casei did. As seen in Figure
3.12, L. plantarum co-cultures reduced stx2 expression to 55% and 75% of the control,
for the 1:100 and 1:1 ratios, respectively.

6.

Discussion
The study of probiotics, microbes that are beneficial for human consumption, is a

rapidly-expanding subdiscipline of microbiology. Probiotics have been shown to reduce
the shedding and severity of disease in various animal models of E. coli 0157:H7
infections (23, 25, 142, 160, 175, 176). The reduction in disease can in part be attributed
to the effects the probiotics have on the production of virulence factors by the pathogen.
Animal model studies have shown that lactobacilli inhibit the formation of attaching and
effacing lesions in the gut and that this response is due to direct cell-to-cell contact of
lactobacilli and E. coli 0157:H7 (25, 142). Likewise, studies have shown that the in vivo
production of Stx-2 by E. coli 0157:H7 is reduced in animals co-colonized with a
probiotic organism (4, 30, 110, 141, 160, 176).
In the present study, E. coli 0157:H7 was grown in co-culture with two
probiotics, L. casei and L. plantarum, to determine the effect of the lactobacilli on the
overall growth of E. coli 0157:H7 as well as on the expression of the stx2 gene, and the
production of Stx-2.

It was hypothesized that the lactobacilli would reduce stx2

expression and Stx-2 production by the E. coli. It was similarly thought that co-culture of
the E. coli with the probiotics would reduce the overall numbers of E. coli 0157:H7 cells
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Figure 3.12. Real Time PCR Analysis of E. coli 0157:H7 and L. plantarum CoCultures. Both the 1:100 and 1:1 E. coli to L. plantarum ratio significantly reduced stx2
transcripts compared to the E. coli only controls. These results were similar to what was
seen with L. casei co-cultures.
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in culture when compared to growth of the pathogen in culture alone. It was indeed
determined that growth of the E. coli 0157:H7 was reduced in co-culture with the
lactobacilli, and this growth inhibition was related to the starting concentrations of both
organisms. ELISA analysis confirmed that when the E. coli 0157:H7 started as either
1% (1:100) or 50% (1:1) of the total number of cells in culture, then Stx-2 production
was significantly reduced.

When the E. coli outnumbered lactobacilli 100:1, no

significant change in Stx-2 production was noted when compared to the control. Real
Time PCR showed similar results for the toxin gene expression at these organism
concentrations.

It was clear that the mode of action of cell-to-cell contact of the

lactobacilli on the virulence of E. coli 0157:H7 was complex, and involved a reduction in
pathogen growth, stx2 expression, and toxin production. However, subsequent ELISA
experiments with cell-free lactobacilli supernate and acidified media indicated that this
reduction in Stx-2 was also due to secreted compounds from the lactobacilli.
Cell-free supernates from the lactobacilli, and both organic acids, acetic acid and
lactic acid, reduced Stx-2 production to 75-80% that normal (no supernate, not acidified)
medium. This reduction in part accounts for the reduction of Stx-2 seen in co-culture
models, but does not account for the full decrease in Stx-2 seen in these studies (as low as
20% Stx-2 concentration compared to the pure culture supernate). The hypothesis that
lactobacilli reduce Stx-2 production by cell-to-cell contact was not disproven by these
studies.

However, it was determined that the production of organic acids by these

probiotics may also play a role. Interestingly, growth of the pathogen in media acidified
to the same pH, but using an inorganic acid (HC1) showed no affect on the bacterial
production of Stx-2. It has been shown that E. coli has various overlapping means of
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inorganic acid resistance, but that these resistance mechanisms are not always as potent
against organic acids (9, 51). Unlike inorganic acids, organic acids can enter the E. coli
cell in an undissociated state and then dissociate.

This results in a lowering of

cytoplasmic pH, which can kill the E. coli cell, or alter its membrane composition (9, 34,
51, 131). Indeed, Stx secretion is reduced when the lipid composition of the E. coli
membrane is altered (60, 173). It appears likely that this mode of action of organic acids
on E. coli 0157:H7 contributes to the reduction in Stx-2 seen when the pathogen was
grown in lactobacilli supernates, or when it was grown in organic acid-containing media.
Real Time PCR analysis of the stx2 gene provided additional insight into the
mechanisms surrounding the effect of lactobacilli on Stx-2 production. These studies
showed that the lactobacilli were able to alter the expression of stx2 gene in E. coli when
they were in equal or greater numbers to the pathogen. It is possible that the presence of
the lactobacilli disrupted E. coli cell-to-cell signaling, and therefore reduced stx2
expression. Regulation of virulence by quorum sensing has been noted in numerous
pathogens (98), and specifically studies have shown that quorum sensing molecules
produced by both the pathogenic and benign strains of E. coli are able to upregulate stx2
expression (47, 48, 147, 148). In a study by Medellin-Pena et. Al (94), probiotics were
demonstrated to "quorum-quench" E. coli cell-to-cell communication, resulting in a
reduction in the virulence of the organism.

Stx-2 production was not significantly

affected by the quorum-quenching in that study, however a different species of
Lactobacillus was used than in the present study, which could account for the difference
in observed results.
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Probiotics have been demonstrated to reduce virulence of E. coli 0157:H7 in
numerous other cases (4, 30, 73, 88, 142, 175, 176). Saccharomyces bouldarii was
shown to reduce signaling in T84 cells that allows enterohemorrhagic E. coli to maintain
adherence to the cells. Although S. bouldarii did not affect the number of E. coli cells, it
did reduce the virulence of the pathogen by interfering with adhesion (30). Lactobacilli
have specifically been shown to affect adherence of pathogenic strains of E. coli as well;
in one study, the production of attaching and effacing lesions was significantly reduced in
the presence of L. rhamnosus and L. acidophilus (142). Probiotics have even been
suggested to cross-domain signal with intestinal cells, causing those cells to increase their
production of mucus, which is inhibitory to pathogen adherence and persistence (88).
Within the course of an infection in the human gastrointestinal tract, E. coli
0157:H7 is exposed to numerous signaling molecules, all with the possibility of
modulating virulence in some manner. Even human hormones such as epinephrine and
norepinephrine have been shown to upregulate the virulence genes in enterohemorrhagic
E. coli (7). It is possible that probiotics such as lactobacilli contribute to the mass of
signaling that occurs in this complex environment, and that they ate able to alter cell-tocell communication of the E. coli 0157:H7 and thus reduce its ability to regulate the
production of its virulence factors, including Stx-2.
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CHAPTER 4

IMPACTS OF GLUCOSE, GLYCEROL AND
CYCLIC ADENOSINE MONOPHOSPHATE ON STX-2 PRODUCTION BY
ESCHERICHIA COL7 0157:H7

1.

Abstract
Previous research has shown that growth of lambda-infected non-pathogenic E.

coli in the presence of glucose led to a significantly higher rate of induction of the lytic
phase of lambda, whereas growth in glycerol resulted in phage lysogeny. In the present
study, it was hypothesized that growth of E. coli 0157:H7 in glycerol would likewise
maintain 933-W (a lambda-like phage harboring the stx2 gene) in a lysogenic state and
therefore reduce the production of Stx-2. Likewise, increasing the availability of cAMP
to the organism would decrease Stx-2 production by simulating intracellular low-glucose
availability. E. coli 0157:H7 was grown in glucose or glycerol-supplemented minimal
media, or in Luria Bertani (LB) broth supplemented with cAMP. The stx2 gene was
assessed using q-PCR, and the production of Stx-2 toxin was measured using a capture
ELISA as well as by MTT cytotoxicity assay. It was determined that Stx-2 production
increased with increasing availability of glucose; indeed, cultures of the organism in
minimal media with 1.0% glucose yielded 2-times higher concentrations of Stx-2
compared to those grown in 0.04% glucose. Varying concentrations of glycerol had no
effect on Stx-2 production.

As predicted, increasing the concentrations of cAMP

decreased the amount of Stx-2 produced. These studies suggest that glucose but not
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glycerol stimulates Stx-2 expression by lambda-like phage 933-W carrying strains of E.
coli 0157:H7.

2.

Introduction
The stx2 gene is located on a lambda-like bacteriophage inserted as a prophage

into the chromosome of E. coli 0157:H7. When the organism is metabolically stable, the
prophage remains in a lysogenic state. However, if the E. coli host is subjected to stress,
the prophage converts to a lytic state and is excised from the chromosome. During
excision, the stx2 gene is co-expressed with phage genes, leading to an increase in toxin
production (78, 104, 120, 164). Upregulation of stx2 gene expression is a consequence of
activation of the previously-dormant prophage and the switch from a lysogenic state to a
lytic state. Numerous factors have been cited as inducers of the bacteriophage (that is,
factors that encourage the phage to convert from lysogeny to a lysis) (47, 57, 74, 71).
In 2001 Czyz et. al (29) conducted a study on the rates of lysis and lysogeny by a
lambda phage in a non-pathogenic E. coli strain. The purpose of the research was to
determine whether the growth medium influenced the lytic cycle of lambda
bacteriophages within E. coli. The authors concluded that lysis occurred more frequently
in cultures of E. coli grown in minimal media (M9) with glucose than in cultures of E.
coli grown in M9 with glycerol. Concentrations of glucose are inversely proportional to
the concentrations of cyclic adenosine monophosphate (cAMP) in bacterial host cells. It
was reasoned that because cAMP indirectly inhibits proteases that breakdown the ell
protein, and because the protein ell is an integral part of the regulatory system that

109

encourages lambda lysogeny, by increasing glucose in the cell, and therefore lowering
cAMP, lysis of the phage was promoted through the degradation of ell (29).
It is possible that such conditions apply to the pathogenic E. coli 0157:H7 (EHEC
strains) and the lambda-like 933-W prophage it carries. Indeed, the genetic system
controlling lysogeny of the E. coli 0157:H7 BP-933W bacteriophage is similar to that of
lambda in that it is a complex, self-repressing, and self-regulating system. When the
regulatory proteins ell and cIII are expressed at low levels they activate the repressor cl.
cl in turn binds and represses the promoters, ProL and ProR, to stop the transcription of
the majority of the phage genome, including ell and cIII and thus the toxin gene, stxl (78,
86, 164). In the case of reduced levels of cAMP (due to high levels of glucose), more
cellular proteases are present, and the rate of ell degradation is increased. Without the ell
protein, the expression of cl repressor is arrested, and the late phage genes are expressed
including stxl.

Because the stxl gene is located between the late phage promoter and

phage-excision genes, it is co-transcribed when these genes become activated (86, 164).
Therefore, it is possible that stxl is upregulated under conditions of high glucose
availability. In conditions of low glucose availability and high cAMP concentrations,
stxl may be downregulated.
In the current study, the production of the toxin Stx-2 and the activity of the stxl
gene were measured when the organism E. coli 0157:H7 was grown in M9 containing
either 0.04%, 0.2% or 1.0% glucose, or 0.04%, 0.2% or 1.0% glycerol. Likewise, E. coli
0157:H7 was grown in LB medium in the absence of exogenous cAMP or containing
ImM or lOmM exogenous cAMP. Stx-2 production was measured by both cytotoxicity
assays and by enzyme-linked immunosorbent assay (ELISA). The activity of the stxl
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gene was measured by quantitative Real Time PCR, and for these investigations, the serC
(serine synthase) was used as a housekeeping gene; it is constitutively transcribed despite
growth conditions. All results were expressed as a function of serC activity to allow for
differences in experimental techniques (efficacy of RNA extraction, cDNA synthesis,
etc.).

3.

Hypothesis
It was hypothesized that growth of the pathogenic E. coli 0157:H7 in glucose

would lead to an increase in stx2 expression and Stx-2 production, compared to growth of
the organism in glycerol. This upregulation in stx2 was believed to be linked to induction
of the lytic phase of the 933-W phage that resides within the E. coli 0157:H7
chromosome. Conversely, supplementation of a growth medium with exogenous cAMP
was believed to inhibit the lytic phase of the 933-W phage, and therefore reduce both stx2
expression and Stx-2 production.

4.

Materials and Methods
Media and reagent preparations are provided in detail in Appendix A.

4.1.

Bacterial Cultivation
The E. coli 0157:H7 strains 90-2380 and 43888 stock cultures were acquired and

maintained as described in Appendix B. Overnight and experimental cultures used in
these experiments were grown in Mueller-Hinton broths (MHB), or M9 minimal media
supplemented with glucose or glycerol. All cultures were grown statically at 37°C.
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4.2.

Growth Curves of E. coli Q157;H7 in Glucose or Glycerol Supplemented
Minimal Media
E. coli 0157:H7 strain 90-2380 was inoculated into six separate broths: three

cultures of M9 supplemented with 0.04%, 0.2%, or 1.0% glucose, and three cultures of
M9 supplemented with 0.04%, 0.2%, or 1.0% glycerol, and incubated at 37°C overnight
under static conditions. The following day the cultures were adjusted with pre-warmed
media containing the same carbon source concentrations as they had been grown in to
give an optical density of 0.2 at 600 nm. These cultures were grown for one additional
hour to stimulate the cells into log phase growth and were the centrifuged at 4,000 rpm
for 5 min (EEC Centra). Pellets were resuspended in the identical type and volume of
media as before centrifugation.
Three 200|J,L aliquots from each of these six tubes were immediately removed
and pipetted in triplicate into a sterile 96-well plate (Corning). The plate was placed in a
microplate reader (Tecan), and incubated at 37°C under static for 6 h.

Absorbance

readings at 600 nm were recorded every 15 min. These data were plotted to determine
the growth curves for E. coli 0157:H7 when grown M9 media in the presence of the
various concentrations of each of the two carbon sources.

4.3.

Growth Curves of E. coli Q157:H7 in cAMP Supplemented LB Media
E. coli 0157:H7 was grown and prepared as described in the previous section.

The culture was then divided into three equal 2-mL aliquots. Exogenous cAMP was
added to the second and third aliquots of culture to yield 1 mM and 10 mM final
concentrations, respectively.
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Three 200 \iL aliquots from each of these three tubes were immediately removed
and pipetted in triplicate into a sterile 96-well plate (Corning), and growth density was
recorded over time, exactly as described in section 4.2. These data were plotted to
determine a growth curve for E. coli 0157:H7 when grown in 0 mM cAMP-, 1 raM
cAMP-, and 10 mM cAMP-supplemented LB.

4.4.

Vero Cell Growth and Maintenance
African green monkey kidney (vero) cells were acquired and maintained as

described in Appendix B. In preparation for cytotoxicity assays, log-phase vero cells
were passaged into a 96-well microtiter plate (Corning) seeded into the 96-well plate at a
concentration of 10,000 cells/well, as described in Chapter 2, section 4.2.

4.5.

MTT Cytotoxicity Assay Standards
A MTT assay standard curve was prepared as described in Chapter 2, section 4.5.

This standard curve was used in the analysis of subsequent MTT assays to determine the
number of live vero cells remaining after treatment with Stx-2 containing media.

4.6.

Growth of E. coli Q157;H7 in M9 with Glucose or Glycerol for MTT Assay
E. coli 0157:H7 strain 90-2380 was inoculated into six broths containing 0.04%,

0.2% or 1.0% glucose, or 0.04%, 0.2% or 1.0% glycerol. Cultures were then grown
overnight at 37°C under static conditions. The following day these cultures were adjusted
to an optical density of 0.2 at 595 nm using pre-warmed media containing the same
carbon source concentrations as they had been grown in previously. An additional one
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hour incubation was used to stimulate the cells into log phase growth. These cultures
were centrifuged at 4,000 rpm for 5 min (IEC Centra) and the pellets were resuspended in
the identical type and volume of media as before centrifugation. This served to remove
residual toxin formed during the overnight incubation so that only newly-formed toxin
would be assayed.

These cultures were incubated at 37°C for 24 h. Immediately

following incubation, the cultures were centrifuged at 4,000 rpm at 4°C for 10 min to
pellet the cells. The supernates were removed and sterile filtered through a low-protein
binding 0.2 |0,m filter (Pall). Sterile cell-free supernates were stored at -20°C for use in
MTT assays.

4.7.

Growth of E. coli Q157;H7 in cAMP-supplemented LB for MTT Assay
E. coli 0157:H7 was grown and prepared as described in the previous section,

except LB broth was used in place of M9 medium. The culture was then divided into 3
equal 2-mL aliquots. cAMP was added to the second and third aliquots of culture to give
1 mM and 10 mM final concentrations. Cultures were incubated at 37°C for 24 h at
which time they were centrifuged at 4,000 rpm at 4°C for 10 min to pellet the cells. The
supernates were removed and sterile filtered through a low-protein binding 0.2 |j,m filter
(Pall). Sterile cell-free supernates were stored at -20°C for use in MTT assays.

4.8.

E. coli Q157;H7 Growth in M9 with Glucose or Glycerol MTT Assay
Ten |iL each of supernates collected from the growth of E. coli 0157:H7 in

glucose or glycerol containing media were added in triplicate to confluent vero cells in a
96-well plate. The plate was incubated at 37°C in 7% CO2 (Airgas) for 72 h. Following

114

the 3-day incubation, an MTT assay was performed on the vero cells, as described in
Chapter 2, section 4.7. This assay was used to determine the cytotoxicity supernates
produced from E. coli 0157:H7 cultures grown in the various concentrations of either
glucose or glycerol.

4.9.

E. coli Q157:H7 Growth in cAMP-Supplemented LB MTT Assay
A similar MTT assay to that described in the previous section was performed on

the supernatant fluid collected from the growth of E. coli 0157:H7 in cAMPsupplemented LB medium. The purpose of this experiment was to determine the amount
of Stx-2 in these supernates, to determine if cAMP has an effect on the production of the
toxin by the pathogen.

4.10.

Growth of E. coli Q157:H7 in M9 with Glucose or Glycerol for Real Time
PCR and ELISA
E. coli 0157:H7 strain 90-2380 was grown in glucose- or glycerol-containing

medium and prepared exactly as described in section 4.2.

Immediately following

incubation, 100 |JL of each culture was removed to a sterile microfuge tube and retained
for RNA extraction, which was performed immediately. The remaining 2-mL cultures
were incubated for a total of 24 h, followed by centrifugation and collection of the cellfree supernate, as previously described. The supernates were sterile filtered through a
low-protein binding 0.2 |im filter (Pall), and stored at -20°C for use in ELISA assays.
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4.11.

Growth of E. coli Q157:H7 in cAMP-Supplemented LB for Real Time PCR
and ELISA
E. coli 0157:H7 was grown in cAMP-supplemented LB medium as described in

section 4.3. Immediately following incubation, 100 (0,L of each culture was removed to a
sterile microfuge tube and RNA extraction was performed immediately. The remaining
2-mL cultures were incubated for a total of 24 h, after which cell-free supernates were
collected and stored at -20°C for use in ELISA assays.

4.12.

RNA Extraction and cDNA Synthesis
Bacterial RNA protect (Qiagen) was added to each aliquot of culture to prevent

degradation of mRNA and to halt all transcription within the E. coli cells. RNA was
isolated in the same manner as described in Chapter 2, section 4.9. The RNA was
assayed for contaminating genomic DNA by PCR, as described in Chapter 2, and
samples containing DNA were discarded and the RNA extraction protocol was repeated
on a freshly prepared culture.
cDNA synthesis was performed using the Superscript III cDNA synthesis kit
(Invitrogen) exactly as described in Chapter 2, section 4.9, and samples were tested in a
standard PCR assay to ensure that the cDNA synthesis was successful. cDNA samples
were stored at -20°C until their use in Real Time PCR studies.

4.13.

Quantification of cDNA
cDNA samples were quantified using the Qubit (Invitrogen) High Sensitivity

(HS) DNA quantification kit™, according to the manufacturer's instructions.

A brief
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explanation of the Quibit fluorometer quantification protocol is described in Chapter 2,
section 4.10.

4.14.

cDNA standardization
Carbon source-induced and cAMP-induced cDNA samples were standardized

using nuclease-free water to give a concentration of 100 ng/mL prior to use in Real Time
PCR experiments. Standardized cDNA samples were stored at -20°C.

4.15.

Real Time Polymerase Chain Reaction
Real Time PCR was performed using an Applied Biosystems 7300 Thermocycler

and software, as described in Chapter 2, section 4.12. The primers and dual-labeled
probes used in this assay are described in Appendix C.

4.16.

Enzyme-linked Immunosorbent Assay
Enyzme-linked Immunosorbent Assay (ELISA) was designed based a protocol by

Krishna Moody (102), and is described in detail in Chapter 2, section 4.13. A dilution of
purified Stx-2 (Toxin Technologies) was measured concurrently with the test samples for
accurate quantification of Stx-2 in the E. coli 0157:H7 supernates. The microliter plate
was read spectrophotometrically at 405 nm and the data were recorded.
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5.

Results
Statistical significance was determined as described in Appendix B, Section 5.

5.1.

Growth Curves of E. coli Q157;H7 in Glucose or Glycerol Supplemented
Minimal Media
Several growth curves were constructed to show the growth E. coli 0157:H7 in

glucose- or glycerol-supplemented M9 medium. These curves are shown in Figure 4.1
and clearly show that the growth rate of E. coli 0157:H7 is not affected by the
concentration or type of carbon-source used.

5.2.

Growth Curves of E. coli Q157:H7 in cAMP Supplemented LB
A similar set of growth curves were constructed for the growth of E. coli

0157:H7 in cAMP-supplemented LB medium (Figure 4.2). No significant change in the
growth rate of the organism was seen, regardless of the concentration of exogenous
cAMP.

5.3.

MTT Cytotoxicity Assay
A MTT cytotoxicty was employed to measure the effect of Stx-2-containing

supernates on vero cells. Supernates obtained from E. coli 0157:H7 grown in glucosecontaining media killed significantly more vero cells than those supernates obtained from
E. coli 0157:H7 grown in glycerol-containing media (Figure 4.3). The amount of vero
cells killed was proportional to the amount of glucose present in the growth medium used
to grow the E. coli 0157:H7; higher concentrations of glucose yielded higher kill rates of
vero cells. There was no significant change between varying concentrations of glycerol.
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Figure 4.1. Growth Curve of E. coli 0157:H7 in M9 with Glucose or Glycerol.
E. coli was grown in either glucose or glycerol supplemented M9 media. Note that
growth rate of the organism was not impacted by the type or concentration of the
medium.
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Figure 4.2. Growth Curve of E. coli 0157:H7 in cAMP Supplemented LB. E. coli
was grown in LB medium with either OmM, lmM or lOmM cAMP. No difference was
seen in growth rate for those cultures grown with or without cAMP.
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Figure 4.3. MTT Cytotoxicity Assay: The Effect of Glucose and Glycerol on Stx-2
Production by E. coli 0157:H7. When grown in glucose-containing medium, the E. coli
0157:H7 produces more cytotoxic compounds (likely Stx-2) than when grown in
glycerol-containing media.
Note that the cytotoxic affects increase with the
concentration of glucose, yet no significant difference is seen between the different
concentrations of glycerol.
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The concentration of cAMP appeared to exert an inversely proportional reaction
on the cytotoxicity of the E. coli 0157:H7 supernates, as seen in Figure 4.4. When
cultured without cAMP, E. coli 0157:H7 supernate killed approximately 80% of the vero
cell monolayer. The addition of 1 mM cAMP reduced the percentage of vero cell death
to 70%, though this was not found to be statistically significant.

However, E. coli

0157:H7 grown with 10 mM cAMP reduced vero cell death to 37%. This was a
considerable reduction in cytotoxicity.

5.4.

ELISA Analysis of E. coli Q157:H7 Grown with Carbon Source Variation.
Supernates were collected from cultures of E. coli 0157:H7 grown in either M9

with glucose, M9 with glycerol, or LB supplemented with cAMP. These supernates were
assayed for Stx-2 concentration by ELISA, and compared to the previously-constructed
standard curve (Figure 2.6).
As depicted in Figure 4.5, when grown in 0.04% glucose, E. coli 0157:H7
produced 1.9 |j,g of Stx-2. This increased to 3.1 [ig in 0.2% glucose, and to 3.8 |ig in
1.0% glucose.

In 0.04%, 0.2% or 1.0% glycerol, E. coli 0157:H7 produced

approximately 0.5 to 0.8 (Xg of Stx-2. Growth in glucose-containing media produced
significantly more Stx-2 than in the same concentration of glycerol.

Likewise,

production of Stx-2 was dose-dependent on glucose concentration; more Stx-2 was
produced when more glucose was available to the microorganism during growth. The
concentration of glycerol, however, did not significantly change the production of Stx-2.
Production of Stx-2 by E. coli 0157:H7 was also affected by the concentration of
exogeneous cAMP added to the growth medium. When no exogenous cAMP was added,
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Figure 4.4. MTT Cytotoxicity Assay: The Effect of cAMP on Stx-2 Production by E.
coli 0157:H7. Note that the supernates obtained from E. coli 0157:H7 grown in lOmM
cAMP killed significantly less vero cells than those supernates obtained from E. coli
0157:H7 grown in either OmM or ImM cAMP.
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* = p < 0.05
* * = p < 0.005
* * * = P < 0.0005
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Figure 4.5. ELISA Analysis of the Effect of Glucose and Glycerol on the Production
of Stx-2 by E. coli 0157:H7. Cultures grown in glucose-containing M9 produced
significantly more Stx-2 than those grown in glycerol-containing M9. This response was
dose-dependent for glucose but not for glycerol. Increased concentrations of glucose
produced increased concentrations of Stx-2, however, varying the concentration of
glycerol did not effect the production of Stx-2 in those cultures.
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E. coli produced 10 |^g of Stx-2. The addition of ImM cAMP reduced this to 9 |ig of
Stx-2, which was not statistically significant. However, the addition of 10 mM of cAMP
reduced the production of Stx-2 to 6.5 p,g. This data is represented in Figure 4.6.

5.5.

Real Time PCR Analysis of £. coli Q157:H7 Transcripts.
The cDNA collected from glucose and glycerol-induced cultures was used in Real

Time PCR analysis. Two genes were assayed: serC and stx2. All data for stx2 was first
normalized against serC. Once normalized, each glucose sample was compared directly
to its glycerol counterpart for a change stx2 expression. As shown in Figure 4.7, all three
concentrations of glucose resulted in increased stx2 expression when compared to the
equal concentration of glycerol. Growth in 0.04% glucose resulted in 5.5-fold higher stx2
expression than 0.04% glycerol. Likewise, 0.2% glucose and 1.0% glucose yielded 4.8fold and 4.5-fold higher stx2 expression than their glycerol counterparts. There was not,
however, a significant difference in stx2 expression between the three concentrations of
glucose (5.5-fold, 4.8-fold and 4.5-fold).
Figure 4.8 depicts how cAMP appears to exert an opposite effect on stx2
expression than did growth in glucose. In this analysis, the expression of stx2 in 0 mM
cAMP is normalized to one, and the samples grown in 1 mM cAMP and 10 mM cAMP
are compared against that control sample. These results indicate that both 1 mM and 10
mM cAMP reduced stx2 expression to approximately 0.45- and 0.6-fold of the expression
in the absence of cAMP. However, the concentration of cAMP (either 1 mM or 10 mM)
was not statistically significant.
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Figure 4.6. ELISA Analysis of the Effect of cAMP on the Production of Stx-2 by E.
coli 0157:H7. Note that cultures grown in lOmM cAMP produced significantly less Stx2 than those grown in OmM cAMP. No significant change in Stx-2 production was seen
when the pathogen was grown in ImM compared to OmM cAMP.
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Figure 4.7. Real Time PCR Analysis of stx2 in E. coli 0157:H7 Grown in Glucoseor Glycerol-Containing Media. Real Time PCR analysis was performed on the cDNA
of samples grown in glucose or glycerol. Samples from glucose-containing media were
compared to their glycerol counterparts for stx2 expression. Note that all cultures grown
in glucose had significantly higher expression of stx2 than those grown in glycerol.
However, no significant difference was noted between the various concentrations of
glucose.
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Figure 4.8. Real Time PCR Analysis of stx2 in E. coli 0157:H7 Grown in cAMPcontaining LB. Note that both ImM and lOmM cAMP decreased the amount of stx2
transcripts produced by E. coli 0157:H7 when compared to growth in the absence of
exogeneous cAMP.
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6.

Discussion
Czyz et al (29) showed that in non-pathogenic E. coli, a lambda phage was more

likely to stay in a lysogenic state when the E. coli was grown in glycerol compared to
glucose. These findings were applied in the present study to the pathogenic E. coli
0157:H7, which harbors a lambda-like phage, 933-W. In E. coli 0157:H7, the stx2 gene
is located within the 933-W phage structural genes (49). It is expressed at low, baseline
levels unless the phage switches from a lysogenic to a lytic state. When this switch
occurs, the phage structural genes are transcribed, and the stx2 gene is consequently cotranscribed (78, 104, 120, 164). It was hypothesized that this switch from lysogeny to
lysis would occur more readily when the E. coli 0157:H7 was grown in glucosesupplemented media compared to glycerol-supplemented media, and that this would be
demonstrated by an increase in stx2 expression and Stx-2 production. Similarly, it was
thought that this increase in stx2 expression and Stx-2 production in the presence of
glucose would be inversely linked to a decrease in cAMP, and that increasing
concentrations of cAMP could cause the lambda-like phage to remain lysogenic, thereby
decreasing stx2 expression and Stx-2 production.
These studies showed that indeed, growth of the E. coli 0157:H7 in glucosesupplemented media increased stx2 expression and Stx-2 production compared to growth
in glycerol-supplemented media. It is likely that high levels of glucose reduced the
intracellular concentration of cAMP in E. coli 0157:H7. The presence of cAMP reduces
the concentration of intracellular proteases, including those that degrade ell.

The

degradation of ell causes a reduction in the production of the repressor cl, which is
responsible for repressing expression of the phage lysis genes, including stx2 (78). This
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hypothesis is confirmed by the upregulation of stxl seen in the presence of glucose, and
the opposite downregulation of stxl

seen in the presence of cAMP.

concentrations

overall

of

cAMP

decreased

Stx-2 production,

and

Higher
increasing

concentrations of glucose caused the E. coli 0157:H7 to produce increasingly more Stx2, and also led to greater vero cell death in cytotoxicity assays.
Interestingly, this dose-dependent response to glucose was not mimicked in stxl
expression studies; all concentrations of glucose led to higher stxl expression than when
grown in glycerol, but this upregulation was not significantly different between the
various concentrations of glucose. It is possible that because the Real Time PCR studies
were performed after only 1 h of growth that the differences between glucose
concentrations were not as defined as after 24 h of growth, as in the ELISA and MTT
assays. A similar pattern was detected in the cAMP-supplemented media studies. In
Real Time PCR studies, cAMP decreased stxl expression, yet this decrease was not
dependent on cAMP concentration (both ImM and lOmM cAMP decreased stxl
expression), whereas in ELISA and MTT studies, the ImM cAMP concentration was not
sufficient to cause a significant change from the OmM cAMP culture. It required lOmM
cAMP to cause a significant decrease in Stx-2 production and a significant decrease in
vero cell killing.
The information obtained from these studies may be applied in a practical manner
to the problem of E. coli 0157:H7 carriage in dairy and beef cattle.

It has been

demonstrated that the diet of feedlot cattle can also greatly affect the microbial ecology of
the rumen and colon (22, 155, 154). Numerous studies have shown that the microbial
makeup of the bovine digestive tract is drastically different when fed a grain (corn) diet
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compared to a forage (hay, grass) diet (22, 33, 36, 77, 154, 155). Cattle are naturally
accustomed to a forage diet, and have few of the pancreatic amylases that are essential for
the proper digestion of the high concentration of starch found in grain diets (61). As
such, undigested starch is often passed from the rumen through the small intestines into
the colon of these cattle where it is fermented by microorganisms such as E. coli (61).
This kind of diet has been correlated with increased E. coli 0157:H7 carriage and
shedding by these feedlot cattle (6). In fact, 100-fold higher concentrations of E. coli
populations (both benign and human pathogen strains) were recovered when the cattle
were fed a corn and soybean (grain) diet compared to a high-quality hay diet (33). The
fermentation of starch in the colon creates an increasingly acidic environment that allows
these E. coli to become more acid-resistant (33, 82). In a study by Diez-Gonzalez et. al
(33), grain-feeding of cattle increased the ability of E. coli to survive an artificial gastric
shock (mimicking the conditions of the human stomach) by 1000-fold. However, when
the researchers switched the cattle back to a hay diet, E. coli populations declined 1000fold, and the number of acid-resistant E. coli decreased by 100,000-fold in 5 days (33,
22).

It should be noted that in this study, no differentiation was made between

populations of non-pathogenic E. coli and enterohemorrhagic E. coli. However, these
nonpathogenic strains of E. coli have been shown to increase stx2 expression through
quorum sensing, and thus may be significant (47, 48). Likewise, studies have shown that
Stx-harboring phages released from enterohemorrhagic E. coli are able to infect
nonpathogenic strains of E. coli, which subsequently become Stx-producing strains (46,
48).
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The microbial population of other microorganisms in the cattle digestive tract is
also affected by a diet change (36, 77, 154, 155). In 2004, Elias (36) showed that cows
fed an 85% molasses diet (extremely high in sucrose and glucose) had no populations of
lactobacilli present. As previously demonstrated, lactobacilli may aid in the attenuation
of virulence of some pathogens. Likewise, Gregory et. al (53) showed that a diet of hay
increased enterococci populations in the cattle rumen, and that these enterococci were
inhibitory to E. coli (53). It is possible that a high-glucose diet not only increases the
pathogenicity and numbers of enterohemorrhagic strains of E. coli, but also decreases the
probiotic organisms that are capable of diminishing its virulence.
In the present study, glucose, present in much higher quantities in grain diets, was
shown to increase the expression of stx2, and therefore increased the production of 933W phage.

Cattle that are fed a high glucose diet have increased numbers of both

pathogenic and nonpathogenic E. coli, and it is possible that this can lead to increased
virulence in enterohemorrhagic E. coli strains (through upregulation of Stx-2 production
and increased acid resistance) (33, 46, 48). Likewise, these grain-based diets diminish
populations of beneficial microbes (36, 53), furthering the colonization of pathogenic
organisms. A strong argument can be made that a grain diet leads to a greater likelihood
of E. coli 0157:H7 contamination in human food products and should be evaluated
further.
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CHAPTER 5

GENERAL DISCUSSION AND FUTURE STUDIES

1.

Discussion
E. coli 0157:H7 is a food and water borne pathogen that causes symptoms

ranging from mild diarrhea to severe hemorrhagic colitis (127). These infections can
result in devastating sequealae and deadly complications such as HUS and TTP (13, 71,
101, 123, 172). The severity of disease is linked intimately with the production of its
principle virulence factor, Stx-2. Stx-2 is an AB5 toxin that inhibits cellular protein
synthesis in affected cells (14). Currently, treatment for E. coli 0157:H7 is palliative;
antibiotic treatment to reduce pathogen numbers is controversial, as it is believed that
antibiotics may increase the release of Stx-2 from E. coli 0157:H7 (57, 74, 132).
The purpose of this study was three-fold: i) to assess the effects of various classes
of antibiotics on stx2 expression and Stx-2 production; ii) to assess the probiotic
microorganisms L. casei and L. plantarum for their effects on the reduction of stx2
expression and Stx-2 production; and iii) to analyze stx2 expression and Stx-2 production
when E. coli 0157:H7 is grown with either glucose, glycerol, or in the presence of
exogenous cAMP. These three facets were examined by MTT cytotoxicity assay, ELISA
analysis and Real Time PCR.

The present study elucidated a number of factors that regulate stx2 expression,
including the impact of several classes of antibiotics, the effect of co-culture with
lactobacilli, and the nature of growth substrates used for pathogen growth. These three
seemingly disparate factors, however, appear to be more closely linked than previously
appreciated. It was determined that DNA-affecting antibiotics increase stx2 expression
and Stx-2 production, and this is linked to an upregulation in the SOS DNA repair
response. Likewise, a connection was also observed between the upregulation of stx2
and cell membrane integrity disrupting antibiotics, gentamicin and polymyxin B, though
this was not tied to DNA damage, as the dinD gene was not upregulated concurrently
with stx2. Ultimately, these antibiotics did not increase the overall Stx-2 released from E.
coli 0157:H7. Interestingly, growth of E. coli 0157:H7 in organic acid-containing media
(either artificially acidified, or acidified through the growth of lactobacilli) also inhibited
the release of Stx-2. As with gentamicin and polymyxin B, organic acids are thought to
disrupt the lipid composition and structure of bacterial cell membranes, which may
interfer with the assembly or release of Stx-2 toxin molecules (66, 67, 131, 137, 173). It
was clear that disruption of the bacterial cell membrane, either through the action of
antibiotics or organic acid, interferes with the secretion of Stx-2.
The reduction of Stx-2 seen by co-culture with probiotics was in part attributable
to the production of organic acids, but was in part a response to mechanisms as yet
unknown resulting from the lactobacilli. It appears from this research that cell-to-cell
contact is required for full reduction in Stx-2 production; growth of the E. coli 0157:H7
in co-culture with the probiotic microorganisms L. casei and L. plantarum were found to
decrease Stx-2 release to a greater extent than organic acids alone. It is possible that
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these probiotics interfer with the quorum sensing between E. coli 0157:H7 cells (94).
Quorum sensing has been shown to play a role in the virulence of this and other
pathogens (23, 31, 47, 98) and if the lactobacilli are quorum-quenching the E. coli
signaling molecules, this could explain the reduction in stx2 expression and Stx-2 release.
Interestingly, the microbial population (and therefore the quorum-sensing
potential) in the bovine gut is greatly influenced by the diet of the animal (33, 36, 53,
154, 155). Animals fed high-starch grain diets have increased populations of both benign
and pathogenic E. coli, and decreased populations of probiotic microbes (33, 36, 77).
Conversely, cattle fed a more natural hay-based diet had higher populations of
microorganisms that are proven to inhibit E. coli populations (53). These grain-based
diets contain more starch than the cattle are capable of digesting in the rumen, and
therefore some undigested starch is passed to the colon of the animal where it aids in the
proliferation of E. coli populations (53, 61).

The present study has shown that

concentrations of glucose increase the production of Stx-2, and likely the production of
the 933-W phage.

These Stx-carrying phage have the ability to infect other

nonpathogenic strains of E. coli and confer Stx production upon them (48). It is possible'
that a higher glucose, starch-based diet for cattle may contribute to the pathogenicity of
E. coli 0157:H7, and increase the likelihood of contamination in human food products.
The regulation of stx2 expression and the production of Stx-2 has been shown to
be complex, involving a range of factors from the diet of the host animal, to the microbial
population in that niche, to the treatment options used in human patients infected with
this pathogen. In this research three unique factors, antibiotics, probiotics, and carbon
source, have each been shown to play a role in this network of stx2 regulation, and further
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research is needed to fully understand their connection to each other and the disease that
results from E. coli 0157:H7 and Stx-2.

2.

Future Studies
A multifaceted approach to understanding the regulation of stx2 in E. coli

0157:H7 was implemented in this study.

Numerous factors that either increase or

decrease the expression of the stx2 gene, and alter the production of Stx-2 by the
organism have been uncovered. Many interesting lines of work have developed from this
work and warrant further investigation.

2.1.

Synergistic Treatment of E. coli Q157:H7 Infections with Rifampin and a
Cephalosporin
This research has shown that rifampin could be a viable treatment option for

patients infected with E. coli 0157:H7, as it has been found to decrease stx2 expression.
However, due to ease of resistance to rifampin, this drug is often used in synergy with
other antibiotics. In particular, cephalosporins and rifampin have been used together in
synergy for treatment of other infections (24), including difficult-to-treat infections, such
as those caused by P. aeruginosa (41) and MRS A (15). In the current study, cefotaxime
(a third-generation cephalosporin) was shown to not increase stx2 expression or Stx-2
production more than the uninduced control. Future studies could examine the effect of a
synergistic combination of rifampin and cefotaxime (or another cephalosporin) on the
expression of stx2 and release of Stx-2 from E. coli 0157:H7 cells. This could lead to a
viable treatment option for an infection that currently has no accepted curative treatment.
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2.2.

Cell Membrane Disrupting Compounds and Stx-2 Production
Polymyxin B and gentamicin both have the ability to disrupt cell membranes (66,

67, 137). In these studies, both of these antibiotics decreased Stx-2 production compared
to the controls.

Interestingly, organic acids were also demonstrated to reduce the

production of Stx-2. Polymyxin B, gentamicin, and organic acids all alter the cell
membrane of these microbes, and this is possible that disruption of the lipid composition
of bacterial membranes affects secretion of the toxin, as it does in the case of pertussis
toxin (131, 173). One study showed that the twin arginine translocation (TAT) system
contributed to the secretion of Stx-2 (121), however, further research on the effect of
membrane-altering compounds on the TAT system is necessary to completely understand
how these compounds interfere with Stx-2 release from enterohemorrhagic E. coli.

2.3.

The Role of Quorum-sensing on stx2 Regulation
Microbiology has realized the great effect that co-colonizing microbes play on

one another through quorum sensing (98). Studies have shown that quorum sensing
molecules produced by nonpathogenic E. coli can upregulate stx2 expression in E. coli
0157:H7 (48). Conversely, in vivo co-culture of the pathogen with probiotic organisms,
such as lactobacilli and species of Bifidobacterium, has been shown to decrease Stx-2
expression in animal models (4, 110).

This research demonstrated that cell-to-cell

contact of lactobacilli with E. coli 0157:H7 was necessary for the full reduction in Stx-2
production. It is possible that the probiotics actively released quorum sensing molecules
that downregulated stx2 expression. Perhaps the lactobacilli played a more passive role;
it is possible that the probiotics absorbed the quorum sensing molecules released by the

137

other E. coli, which in turn reduced the amount of molecules available for signaling the
E. coli to upregulate its stx2 expression.

Studies aimed at elucidating the role that

quorum sensing of these lactobacilli play on the expression of stx2 would be beneficial to
understanding how probiotics attenuate pathogen virulence.

2.4.

STEC in the Gut of Grain-Fed Cattle: stx2 Transduction
Previous studies have implicated that nonpathogenic E. coli contribute to the

virulence of enterohemorrhagic E. coli by upregulating stx2 expression (48). These
nonpathogenic strains also have the ability to be infected by the Stx-carrying phage
released by the pathogenic strains, and thereby become Stx-producing strains themselves
(48). Grain-fed cattle have been shown to have increased populations of E. coli, and
decreased concentrations of probiotic organisms (33, 36, 53, 77). Likewise, the present
study has concluded that elevated concentrations of glucose lead to an increased release
of Stx-2, and likely to an increased release in the 933-W phage. A study on the rate of
stx2 transduction into previously-nonpathogenic E. coli within the gut of grain-fed cattle
would provide valuable information as to the role of cattle diet on the prevalence of
enterohemorrhagic strains of this pathogen.
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APPENDIX A
MEDIA AND REAGENTS

1.

Bacteriologic media

1.1.

Trypticase soy agar (TSA) plates
Trypticase soy agar (TSA) plates were made for general growth purposes. This

medium was purchased in dehydrated form from Difco and prepared according to the
manufacturer's instructions (40.0g dehydrated media into 1.0L distilled H2O).

The

solution was autoclaved at 121.0°C for 20 min and dispensed into sterile Petri dishes.
TSA plates were stored at 4°C.

1.2.

Trypticase soy broth (TSB)
Trypticase soy broth (TSB) was made for general growth purposes. This medium

was purchased in dehydrated form from Difco and prepared according to the
manufacturer's instructions (30.0g dehydrated media into 1.0L distilled H2O).

Fifty

milliliters of the solution was dispensed into 250mL Erlenmeyer flasks and autoclaved at
121.0°C for 20 min. Broths were stored at room temperature.
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1.3.

Luria-Bertani (LB) broth
Luria-Bertani (LB) broth was made for general growth purposes. This medium

was prepared according to the recipe below.

Fifty milliliters of the solution was

dispensed into 250mL Erlenmeyer flasks and autoclaved at 121.0°C for 20 min. Broths
were stored at room temperature.
Formulation for LB:
20 g tryptone (Difco)
lOg yeast extract (Difco)
lOg NaCl (Sigma)
2000mL d.H 2 0

1.4.

Trypticase soy broth (TSB) with 15% glycerol
Trypticase soy broth (TSB) with 15% glycerol was made for the cryopreservation

of bacterial strains. The base of this medium (TSB) was purchased in dehydrated form
from Difco and prepared according to the manufacturer's instructions (30.0g dehydrated
media into 1.0L distilled H2O). Fifteen milliliters of glycerol (EM) was also added. The
solution was transferred to a glass bottle and autoclaved at 121.0°C for 20 min. The broth
was storedat room temperature.

1.5.

Mueller-Hinton (MH) agar plates
Mueller-Hinton (MH) plates were made for general growth purposes and use in

antibiotic studies. This medium was purchased in dehydrated form from Difco and
prepared according to the manufacturer's instructions (30.0g dehydrated media into 1.0L
distilled H2O). The solution was autoclaved at 121.0°C for 20 min and dispensed into
sterile Petri dishes. MH plates were stored at 4°C.
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1.6.

Mueller-Hinton broth (MHB)
Mueller-Hinton broth (MHB) was made for general growth purposes and for

antibiotic studies. This medium was purchased in dehydrated form from Difco and
prepared according to the manufacturer's instructions (22.0g dehydrated media into 1.0L
distilled H2O). Fifty milliliters of the solution was dispensed into 250mL Erlenmeyer
flasks and autoclaved at 121.0°C for 20 min. Broths were stored at room temperature.

1.7.

Brain-heart infusion (BHI) broth
Brain-heart infusion (BHI) was made for growth of lactobacilli and lactobacilli

co-cultures. This medium was purchased in dehydrated form from Difco and prepared
according to the manufacturer's instructions (37.0g dehydrated media into 1.0L distilled
H2O). Fifty milliliters of the solution was dispensed into 250mL Erlenmeyer flasks and
autoclaved at 121.0°C for 20 min. Broths were stored at room temperature.

1.8.

deMan-Rogosa-Sharpe (MRS) broth
The deMan-Rogosa-Sharpe (MRS) broth was purchased in dehydrated form from

Acumedia. It was prepared according to the manufacturer's instructions: 55g was added
into 1 liter of d. H2O. It was autoclaved at 121°C for 15 min to sterilize. The broth was
stored at room temperature.
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1.9.

M9 lOx salts
M9 minimal media base lOx salts were made according to the formulation below.

The solution was autoclaved at 121°C for 20 min.
Formulation for M9 lOx Salts:
60 g Na 2 HP0 4 (Sigma)
30 gKH 2 P0 4 (Sigma)
5 g NaCl (VWR)
10 g NH4C1 (Sigma)
1000 mL d.H 2 0

1.10.

M9 Base
M9 base was made according to the formulation below.
Formulation for M9 lOx Salts:
100 mL lOx Salts
10 mL lOmMCaCL.
2 mL 1M MgS0 4

2.

Reagents

2.1.

0.5M ethylene diamine tetraacetic acid (EDTA). pH 8.0
Ethylene diamine tetraacetic acid (EDTA) was made at a concentration of 0.5M.

The buffer was prepared according to the formulation below and adjusted to pH 8.0 with
approximately 5 g of NaOH pellets (Sigma). The solution was autoclaved for 20 min at
121.0°C and stored at room temperature.
Formulation for 0.5M EDTA, pH 8.0
46.5 g NaEDTA (Sigma)
200 mL distilled H 2 0
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2.2.

Tris-acetate-ethylene diamine tetraacetic acid (TAE) buffer, 50x
Tris-acetate-ethylene diamine tetraacetic acid (TAE) buffer, 50x, was made as a

concentrated buffer for agarose electrophoresis gels. The buffer was prepared according
to the formulation below. The buffer stored at room temperature, and diluted to lx with
distilled H2O for use.
Formulation for TAE, 50x:
242 g Tris base (Biorad)
100 mL 0.5M EDTA
57.1 mL Glacial acetic acid (Mallinckrodt)
The solution was heated and mixed to dissolve the Tris base. The pH was
adjusted to 8.5 with a few drops of glacial acetic acid.

2.3.

1M Tris-hvdrochloride (Tris-HCl). pH 6.8
Tris-hydrochloride (Tris-HCl) was made at a concentration of 1M according to

the formulation below. The pH was adjusted to 6.8 by hydrochloric acid (VWR). It was
stored at room temperature.
Formulation for 1M Tris-HCl:
15.76 g Tris-HCl (Research Organics)
100 mL distilled H 2 0

2.4.

10% (w/v) Sodium dodecvl sulfate (SDS)
A 10% solution of sodium dodecyl sulfate (SDS) was prepared by the recipe

below. This solution was stored at room temperature.
Formulation for 10% SDS:
10 g SDS (Biorad)
100 mL d.H 2 0
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2.5.

Tris-ethvlene diamine tetraacetic acid (TE) buffer. ImM EDTA. lOmM Tris
RNase-free TE buffer was prepared for use in RNA extractions. All weighing

materials (weigh boat, spatulas) were soaked overnight in a 1% solution of
diethylpyrocarbonate (DEPC) to inactivate any RNases. These materials were autoclaved
to inactivate the DEPC. A 2mM EDTA solution, and a 20mM Tris solution were
prepared separately according to the formulations below.

The EDTA solution was

autoclaved at 121°C for 15 min to inactivate the DEPC. The Tris solution was made with
certified RNase-free Tris and DEPC-treated (inactivated) water, as Tris is sensitive to
DEPC. They were combined in a ratio of 1:1 under sterile conditions to yield the final
concentrations of ImM EDTA and lOmM Tris in the finished TE buffer.
Formulation for 2mM EDTA solution:
0.149 g EDTA (Sigma)
200 mL d. H 2 0
2 mL DEPC (active)
Formulation for 20mM Tris (Sigma)
0.48 g Tris
200 mL DEPC-treated d.H 2 0
2.6.

ION Sodium hydroxide (NaOH)
A ION solution of NaOH was made according to the recipe below. It was stored

at room temperature.
Formulation for ION NaOH:
50.0 g NaOH pellets (J.T. Baker)
125 mL d. H 2 0
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2.7.

1% (w/v) Sodium dodecvl sulfate (SDS)
A 1% solution of sodium dodecyl sulfate (SDS) was prepared by the recipe

below. This solution was stored at room temperature.
Formulation for 1% SDS:
1 g SDS (Biorad)
100 mL d.H 2 0

2.8.

MTT

(3-(4.5-Dimethvlthiazol-2-vl)-2.5-diphenvltetrazolium

bromide)

5

mg/Ml
A solution of MTT was made at a concentration of 5 mg/mL, according to the
formulation below. The solution was sterile filtered through a 0.2|im filter (Pall) and
stored at 4°C, protected from light.
Formulation for MTT, 5 mg/mL:
50 mg MTT (Sigma)
10 mL d.H 2 0
2.9.

MTT Lysine solution
MTT lysing solution was prepared according to the formulation below. The final

concentrations of the components were 20% SDS and 50% Dimethylformamide (DMF).
This solution was stored at room temperature.
Formulation for MTT lysing solution:
8 g SDS (Biorad)
20 mL DMF (Sigma)
20 mL d.H 2 0
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2.10.

Lysis Buffer
Lysis buffer was formulated for the lysing of Gram negative bacteria using the

recipe below. This buffer was stored at room temperature.
Formulation for lysis buffer:
250 |iL 10% SDS
50 ^L ION NaOH
9.7 mL d. H 2 0

2.11.

Phosphate buffered saline (PBS)
Phosphate buffered saline (PBS) was made using the recipe below. The pH was

adjusted to 7.4 using hydrochloric acid. The solution was transferred to a glass bottle and
autoclaved at 121.0°C for 20 min. The PBS was stored at room temperature.
Formulation for lx PBS:
1.44 g Sodium phosphate, dibasic (Na2HP04)
8 g Sodium chloride (NaCl)
0.2 g Potassium Chloride (KC1)
0.24 g Potassium Phosphate, Monobasic (KH2PO4)
1.0Ld.H 2 O
2.12.

Antibiotic preparations
Antibiotics used in these studies were prepared to a stock concentration of 20

mg/mL in an appropriate solvent, as seen in Table Bl below. Each antibiotic stock
solution was sterile filtered using a 0.2ja,m (Pall), then serially diluted 1:10 in sterile
d.H20 to 2|ig/mL. All dilutions of each antibiotic were stored at -20°C.
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Table Bl. Antibiotic Preparations
SoUent

\ntibiotics
Cefotaxime

Manufacturer
Sigma

Water

Ciprofloxacin

Cellgro

O.lMNaOH to dissolve

Chloramphenicol

Calbiochem

95% ethanol

Gentamicin

Sigma

Water

Polymyxin B

Sigma

Water

Rifampicin

Sigma

Methanol

Norfloxacin

Sigma

0.1M NaOH to dissolve

Trimethoprim

Sigma

0.1MHC1 to dissolve
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2.13.

lOOmM Magnesium sulfate (MgSOa)
A lOOmM solution of magnesium sulfate was made according to the formulation

below. It was sterile filtered through a 0.2}xm filer (Pall) and stored at room temperature.
Formulation for lOOmM MgS0 4 :
1.204 g MgS0 4 (Mallinckrodt)
100 mL d.H 2 0

2.14.

lOmM Calcium chloride (CaCh)
A lOmM solution of calcium chloride was made according to the formulation

below. It was autoclaved at 121°C for 20 min and stored at room temperature.
Formulation for lOmM CaCl2:
0.111 gCaCl 2 (J.T.Baker)
100 mL d.H 2 0

2.15.

1M Magnesium sulfate (MgSO*)
A 1M solution of magnesium sulfate was made according to the formulation

below. It was sterile filtered through a 0.2|im filer (Pall) and stored at room temperature.
Formulation for 1M MgSCU:
12.04 g MgS0 4 (Mallinckrodt)
100 mL d.H 2 0

2.16.

20% (w/v) Glucose
A 20% glucose solution was prepared by adding 20 g of glucose (Sigma) to 100

mL of d.H 2 0. The solution was autoclaved at 121°C for 20 min.
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2.17.

20% (\M Glycerol
A 20% glycerol solution was prepared by adding 20 mL of glycerol (EM) to 100

mL of d.HaO. The solution was autoclaved at 121°C for 20 min.

2.18.

ELISA Primary antibody (11E10)
The murine primary antibody, STX2-11E10, was purchased from Toxin

Technologies. It is specific to the A subunit of the Stx-2 toxin. It was diluted to lmg/mL
in lx PBS for the stock solution, and a working solution was also made as a 1:250
dilution.

2.19. ELISA Blocking buffer
Blocking buffer was made using a 5% dehydrated skim milk solution. 5.0 g of
dehydrated milk (Difco) was added to 100 mL of lx PBS and mixed thoroughly. This
solution was made fresh for each ELISA experiment to prevent contamination of the
buffer.

2.20.

ELISA Secondary antibody
The secondary antibody was STXPC-1, a pooled monoclonal IgG antibody

specific to Stx. It was conjugated to horseradish peroxidase. This antibody was supplied
from Toxin Technologies in liquid form. It was diluted 1:300 in blocking buffer for a
working stock. It was stored at 4°C.
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2.21. ELISA ABTS Peroxidase Substrate Buffer and Stop Solution
The ELISA substrate buffer was purchase from Pierce.

The concentrated

substrate solution (lOx) was diluted in autoclaved d. H20 to lx stock. One tablet of the
substrate was dissolved in the substrate buffer. A stop solution was also prepared as 1%
SDS.

3.

Cell culture media and reagents

3.1.

Dulbecco's modified Eagle's minimal essential media (DMEM) with 3%
bovine calf serum (BCS)
Dulbecco's modified Eagle's minimal essential media (DMEM) was prepared for

use in vero cell culture. The media was prepared using the formulation below. After
each of the components were added, the media was adjusted to pH 7.2 with 5M HC1
(VWR). The liquid was sterile filtered under vacuum using a 0.2|im filter (Nalgene).
Two 1-liter bottles were autoclaved at 121°C for 20 min prior to the preparation of this
media, and served to hold the filtered media.

The medium was incubated at 37°C

overnight to check for sterility. Following incubation, bovine calf serum (BCS) was
added to a final concentration of 3%. A second overnight 37°C sterility check was
performed before final storage at 4°C.
Formulation for DMEM:
2 bottles of pre-measured powdered DMEM-4.5, high glucose with L-glutamine,
25mM HEPES buffer, without sodium pyruvate (Atlanta Biologicals)
7.40 g sodium bicarbonate (Fisher)
20 mL non-essential amino acids, lOOx (Sigma)
2 L d.H 2 0
60 mL bovine calf serum (Sigma)
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3.2.

Hank's balanced salt solution-modified (HBSS-mod)
Hank's balanced salt solution-modified (HBSS-mod) was prepared for use in vero

cell culture. The media was prepared using the formulation below. After each of the
components were added, the media was adjusted to pH 7.2 with 5M HC1 (VWR). The
liquid was sterile filtered under vacuum using a 0.2(j,m filter (Nalgene). Two 1-liter
bottles were autoclaved at 121°C for 20 min prior to the preparation of this media, and
served to hold the filtered media. The medium was incubated at 37°C overnight to check
for sterility before final storage at 4°C.
Formulation for HBSS-mod:
2 bottles of pre-measured powdered HBSS-modified (No Ca2+, no Mg2+) (Atlanta
Biologicals)
0.70 g sodium bicarbonate (Fisher)
2 L d.H 2 0

3.3.

Trypsin- ethylene diamine tetraacetic acid (trypsin-EDTA)
A trypsin-ethylene diamine tetraacetic acid (trypsin-EDTA) solution was made

according to the formulation below. The solution was sterile filtered using a low protein
binding 0.2|0,m filter (Pall) and transferred into sterile 15-mL conical tubes. The aliquots
were stored at -20°C.
Formulation for trpysin-EDTA:
0.5 g trypsin (Sigma)
0.2 g EDTA (Sigma)
1000 mL HBSS-mod
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3.4.

Trypan blue (0.4%)
A solution of trypan blue was made in lx PBS according to the recipe below. The

solution was sterile filtered using a low protein binding 0.2|0,m filter (Pall). The solution
was stored at room temperature.
Formulation for trypan blue solution:
0.04g trypan blue (Sigma)
100 mL lx PBS

3.5.

Mitomycin C (0.5|Ug/mL)
A solution of mitomycin C was prepared to a concentration of 0.5}ig/mL. The

solution was made according to the formulation below, and stored at 4°C, protected from
light.
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APPENDIX B

ORGANISM ACQUISITION AND VERIFICATION

1.

Maintenance of Bacterial Strains
Two fully virulent strains of E. coli 0157:H7 were used throughout the course of

these experiments, and were acquired from Robert Mooney (UNH-Durham).

Strain

43888 originated from the American Type Culture Collection (ATCC) and does not
contain the genes for stxl or stx2. Strain 90-2380 from the National Laboratories for
Enteric Pathogens (NLEP) produces Stx-2 only (not Stx-1).
Upon receipt, E. coli 0157:H7 strains 90-2380 and 43888 were streaked onto
trypticase soy agar (TSA), and aliquots of bacteria were cryopreserved in trypticase soy
broth (TSB) with 15% glycerol at -20°C and then transferred to -80°C for long term
storage. After 1 week of storage, viability and purity were confirmed by macroscopic
and microscopic examination of colonies grown on TSA from thawed vials.
Stock cultures were streaked onto TSA slants from cryopreservation vials every
four months. Each month, the TSA stock slant was used to streak two TSA plates for
general use. This procedure was used to limit the amount of genetic variability caused by
excess passaging of the organism. Due to the virulence of the organism and its toxin's
classification as a Center for Disease Control and Prevention (CDC) Select Agent (in
quantities greater than 100 mg), its growth and use in the laboratory was closely
monitored, and toxin levels did not exceed 100 mg.
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2.

Verification of Strains by Biochemical Media and Tests
E. coli strains 90-2380 and 43888 were plated onto various selective and

differential mediums to ensure that they exhibited the appropriate biochemical profile of
E. coli. Mediums used include: Eosin methylene blue (EMB) agar plates, MacConkey
(MAC) agar plates, Hektoen enteric (HE) agar plates, triple sugar iron (TSI) agar slants,
Simmon's citrate (CIT) agar slants, motility-indole-ornithine (MIO) tubes, urea (URE)
broth. An oxidase (OX) test was performed using colonies from a TSA plate. All
mediums were incubated at 37°C for 24 h and observed.
The observed biochemical profiles of E. coli strains 90-2380 and 43888 are
shown in Table Bl. The typical biochemical profile for E. coli is included as a reference.

3.

Verification of stx2 gene by Polymerase Chain Reaction
In addition, the strains were tested to ensure that the designated toxin genes were

present by way of Polymerase Chain Reaction (PCR) and agarose gel electrophoresis.
PCR cycles consisted of an initial denaturation at 94°C for five min followed by 30
cycles of 94°C for 30 sec, 54°C for 30 sec and 72°C for 30 sec. A final extension at 72°C
for seven min completed the amplification. Primers previously described by Wang, et al.
were utilized and are described in Table B2. Following amplification, a 2.5% agarose gel
was run and amplicons were visualized by ethidium bromide staining.
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Table Bl. Biochemical Profiles of E. coli Strains
Medium/Test
EMB
MAC
HE
TSI

err

MIO
URE
OX

E. coli 90-2380
Growth, Lac +
Growth, Lac +
Growth, Lac/Suc/Sal +
A/A, Gas+, H2SCitMot +, Ind +, Orn +/UreOx-

E. coli 43888
Growth, Lac +
Growth, Lac +
Growth, Lac/Suc/Sal +
A/A, Gas+, H2SCitMot +, Ind +, Orn +/UreOx-

Expected Result
Growth, Lac +
Growth, Lac +
Growth, Lac/Suc/Sal +
A/A, Gas+, H2SCitMot +, Ind +, Orn +/UreOx-
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Table B2. Primers used for stx gene detection.
Gene to
Amplify
stxl
stx2

Primer Set
Stx la:
Stx lb:
Stx2a:
Stx2b:

TCTCAGTGGGCGTTCTTATG
TACCCCCTCAACTGCTAATA
GCGGTTTTATTTGCATTAGC
TCCCGTCAACCTTCACTGTA

Amplicon
Size
338 bp
115 bp

3.1.

Results of Verification of stx2 gene by Polymerase Chain Reaction
Strain 90-2380 was verified to contain only the genes for stx2. Strain 43888 was

shown to lack genes for either stxl or stx2. Results are shown in Figure B1.

4.

Eukaryotic Cell Cultures: Vero (African Green Monkey Kidney) Cells

4.1.

Vero Cell Growth and Cryopreservation
African green monkey kidney (vero) cells were obtained from the American

Tissue Culture Collection (ATCC) and are designated by number CCL-81. Vero cells are
adherent epithelial cells and are extremely susceptible to Stx. Cellular morphology was
observed to be consistent with vero cell morphology.
Vero cells were maintained in Dulbecco's modified Eagle's modified minimal
essential medium (DMEM) with high glucose, L-glutamine, 25mM hepes, sodium
bicarbonate (3.7g/L), non-essential amino acids, 5% fetal bovine serum (FBS), and
grown at 37°C in a 7% CO2 open system. Vero cells were passaged for 5 rounds before a
new frozen aliquot was seeded as the new stock culture.
Following initial propagation of the vero cells vero cells were diluted to lxlO 6
cells/mL in DMEM with 5% FBS. Cells were combined with 5% dimethylsulfoxide
(DMSO) and lmL aliquots were cryopreserved in liquid nitrogen.

4.2.

Verification of Stx-2-mediated Toxicity on Vero Cells
Verification of Stx-2 production was performed by observation of cytopathic

effects on vero cells when subjected to Stx-2-containing supernate. E. coli 0157:H7
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Figure Bl„ PCR Products of Stx Gene Amplificatioiio 100 bp ladder, from 100
to 1000 bp. Wells 1-2, strain 43888 with stxl and stxl primers, respectively.
Wells 3-4, strain 90-2380 with stxl and stxl primers, respectively. Wells 5-6,
negative control with stxl and stxl primers, respectively. Note that stxl was
amplified by the stxl primers in strain 90-2380. No amplification occurred in
strain 43888.
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90-2380 and E. coli 0157:H7 43888 were grown overnight in TSB at 37°C while
shaking. The cultures were centrifuged and the cells discarded. Supernates were sterile
filtered (0.2(im low-protein bindingfilter, Pall) and applied to confluent vero cell
monolayers in T25 flasks and in 96-well plates. Cytopathic effects were monitored over
the course of 24 h. Blind assays were conducted in which toxin-containing supernate was
applied randomly to wells of a 96-well plate and was identified at 6, 12 and 24 h.

5. Statistics
Each experiment was run three times in triplicate (N=3). Statistical significance was
determined using the T-test. The T-test is appropriate for use when comparing a control
group to the test group.

In the case of these experiments, induced cultures were

compared to their uninduced controls as follows: Antibiotic-induced samples were
compared to the no-antibiotic control; E. coli 0157:H7 and lactobacilli co-culture were
compared to the E. coli-only controls; Growth in glucose was compared to growth in
glycerol; and growth with exogenous cAMP was compared to growth without additional
cAMP. This test was employed for use in Real Time PCR assays, ELISA studies, MTT
cytotoxicity assays, and the co-culture growth competition assays. Significance was
rated on a one star (*) to three star (***) level (as indicated on each graph) with one star
indicating a p value of less than 0.05, two stars indicating a p value of less than 0.005,
and three stars indicating a p value of less than 0.0005.
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APPENDIX C

PRIMERS AND PROBES

1.

Maintenance of Oligonucleotide Primers

1.1.

Design of Oligonucleotide Primers
Oligonucleotide primers and probes were designed using a combination of no-

cost, online software. First, the DNA sequence of the gene of interest was found either
by a BlastN search on the website http://blast.ncbi.nlm.nih.gov/Blast.cgi, or by a gene
search on the website http://cmr.jcvi.org/tigr-scripts/CMR/CmrHomePage.cgi. Secondly,
the

software

"GeneFisher"

on

the

website

http://bibiserv.techfak.uni-

bielefeld.de/genefisher2/, was used to find a preliminary set of possible primer sets. This
software allows the user to input a DNA sequence and assign set parameters (primer
length, amplicon length, melting temperature, etc.), and returns a list of possible primer
sets. This program does not check for secondary structure of primers, so a third program
was used to narrow the list of possible primers to the best set. Using the NetPrimer
software on the website http://www.premierbiosoft.com/netprimer/index.html. the list of
possible primers was checked for interfering structure until a satisfactory primer pair was
discovered.
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1.2.

Acquisition of Oligonucleotide Primers
All primers were ordered through http://www.idtdna.com.

Standard desalting

purification method was ordered for all primer sets.

1.3.

Resuspension of Oligonucleotide Primers
Once received, each oligonucleotide was resuspended in nuclease-free, sterile

water to a final concentration of lOOuM. This was deemed the main stock. That main
stock was then diluted 1:5 in nuclease-free, sterile water to yield a 20uM working stock.

1.4.

Storage of Oligonucleotide Primers
Resuspended oligonucleotides (both main and working stocks) were stored at -

20°C between uses. The main stock was only defrosted to make new working stocks.

2.

Primer Sets

2.1.

StxlA. StxlB
StxlA and StxlB amplify a portion of the stxl gene in E. coli 0157:H7. These

primers were used to verify the presence of the stxl gene in newly-acquired E. coli
0157:H7 strains.
Primer

Sequence 5'to 3 '

Tm

StxlA

TCT CAG TGG GCG TTC TTA TG

54.4°C

StxlB

TAC CCC CTC AAC TGC TAA TA

52.4°C
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2.2.

Stx2A. Stx2B
Stx2A and Stx2B amplify a portion of the stx2 gene in E. coli 0157:H7. These

primers were used to verify the presence of the stx2 gene in newly-acquired E. coli
0157:H7 strains. They were also used to check for genomic DNA contamination in
extracted RNA samples.

Primer

Sequence 5' to 3'

Tm

Stx2A

GCG GTT TTA TTT GCA TTA GC

50.7°C

Stx2B

TCC CGT CAA CCT TCA CTG TA

52.6°C

2.3.

Stx2operon-F. Stx2operon-R
Stx2operon-F and Stx2operon-R were designed based off primers by K. Moody

(102). These primers were used to amplify a large portion (0.8kb) of the stx2 operon,
which was subsequently sequenced.
Primer

Sequence 5' to 3'

Tm

Stx2operon-F

AGA ATT CAG AGC GGG CGT TTT GAG CAG A

63.8°C

Stx2operon-R

AAG GAT CCC CGG CCG GGA TAA TAT TGT GAG TA

64.6°C

2.4.

BigPinP-F, BigPinP-R
BigDinD-F and BigDinD-R were designed to amplify an approximately 0.8kb

piece of DNA flanking the dinD gene in E. coli 0157:H7. They were specifically
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designed to not amplify in L. plantarum or L. casei. This amplicon was further purified
and used as a standard in Real Time PCR experiments.
Primer

Tm

Sequence 5' to 3'

BigDinD-F

TGA ACG AAC ATC ATC AAC CTT T

52.7°C

BigDinD-R

AGC GAT TTG TGC GTA TTG TCA

55.2°C

2.5.

SerCBigPiecel-R
SerCBigPiecel-F

and

SerCBigPiece2-R

were

designed

to

amplify

an

approximately 0.8kb piece of DNA flanking the sercC gene in E. coli 0157:H7. They
were specifically designed to not amplify in L. plantarum or L. casei. This amplicon was
further purified and used as a standard in Real Time PCR experiments.
Primer

Sequence 5'to 3'

Tm

SerCBigPiecel-F

GGA CTA TGC CTG TAT TCG TT

52.0°C

SerCBigPiece2-R

AAT CGG ACG GGA AAG AAT G

52.6°C

3.

Dual-labeled Probes
Dual-labeled probes were designed for use in Real Time PCR experiments. All

probes were acquired, resuspended, and stored identically to oligonucleotide primers, as
listed in this appendix.

Probes were purchased already labeled with a 5' FAM

fluorophore, and a 3' TAMRA quencher.
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3.1.

DinD Probe and Primers
The DinD probe and primers were used to quantify transcripts of dinD during
Real Time PCR assays.
Probe

Sequence 5' to 3'

Tm

DinD-RT-Probe

FAM-CAA GCG TGC GAA GCC AGC AAT-TAMRA

61.4°C

DinD-F

GAA TTG GCA CCG TTA CTG GAT T

55.7°C

DinD-R

CGA AAT GGT CAG ATG CAG CTT

55.8°C

3.2.

SerC Probe
The SerC probe and primers were used to quantify transcripts of serC during Real
Time PCR assays.

•;:g';; Probe

#

Sequjence 5 ' t o 3A

Tm

SerC-RT-Probe

FAM-CGT GTC CGT CGA TTC TGG ATT-TAMRA

57.3°C

SerC-F

CGT CAT CGT CCG TGA AGA TTT

55.2°C

SerC-R

CAT GGA GCC GTT ATC GTT GAG

55.8°C
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3.3.

Stx2 Probe
The Stx2 probe and primers were used to quantify transcripts of stx2 during Real
Time PCR assays.

Probe

Sequence 5' to 3'

Tm

Stx2-RT-Probe

FAM-TGG TTC AAA TCC AGC AAG GGC CA-TAMRA

61.5°C

Stx2-F

AGA GCG AGC GAC TCA TAA TCG

56.6°C

Stx2-R

CTA ATG GCG GTA TGT GAT ATG G

53.0°C
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